[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1075
1. Chung IY, Choi KB, Heo YJ, Cho YH: Effect of PEL exopolysaccharide on the wspF mutant phenotypes in Pseudomonas aeruginosa PA14. J Microbiol Biotechnol; 2008 Jul;18(7):1227-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of PEL exopolysaccharide on the wspF mutant phenotypes in Pseudomonas aeruginosa PA14.
  • Here, we characterized the role of cyclic diguanylate (c-di-GMP) and EPS (PEL) overproduction in the wspF mutant phenotypes of P. aeruginosa PA14 (wrinkly appearance, hyperadherence, impaired motilities, and reduced virulence in acute infections).
  • We confirmed that the elevated c-di-GMP level plays a key role in all the wspF mutant phenotypes listed above, as assessed by ectopic expression of a c-di-GMP-degrading phophodiesterase (PvrR) in the wspF mutant.
  • In contrast, PEL EPS, which is overproduced in the wspF mutant, was necessary for wrinkly appearance and hyperadherence, but not for the impaired flagellar motilities and the attenuated virulence of the wspF mutant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667850.001).
  • [ISSN] 1017-7825
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Polysaccharides, Bacterial; 61093-23-0 / bis(3',5')-cyclic diguanylic acid; EC 3.1.- / Esterases; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


2. Fuchsova B, Fernández ME, Alfonso J, Frasch AC: Cysteine residues in the large extracellular loop (EC2) are essential for the function of the stress-regulated glycoprotein M6a. J Biol Chem; 2009 Nov 13;284(46):32075-88
Hazardous Substances Data Bank. CYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cysteine residues in the large extracellular loop (EC2) are essential for the function of the stress-regulated glycoprotein M6a.
  • Gpm6a was identified as a stress-responsive gene in the hippocampal formation.
  • This gene is down-regulated in the hippocampus of both socially and physically stressed animals, and this effect can be reversed by antidepressant treatment.
  • Previously we showed that the stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation.
  • In the present work, mutational analysis was used to characterize the action of M6a at the molecular level.
  • The presence of cysteines 162 and 202 is essential for the efficient cell surface expression of the M6a protein.
  • In contrast, cysteines 174 and 192, which form a disulfide bridge as shown by biochemical analysis, are not required for the efficient surface expression of M6a.
  • Their mutation to alanine does not interfere with the localization of M6a to filopodial protrusions in primary hippocampal neurons.
  • In non-permeabilized cells, these mutant proteins are not recognized by a function-blocking monoclonal antibody directed to M6a.
  • Taken together, this study demonstrates that cysteines in the EC2 domain are critical for the role of M6a in filopodium outgrowth and synaptogenesis.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2000 Nov 1;351 Pt 3:629-37 [11042117.001]
  • [Cites] Neuroscience. 2000;97(2):253-66 [10799757.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):12-8 [11226150.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4853-62 [11087758.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25005-13 [11325968.001]
  • [Cites] Virus Res. 2001 Nov 28;80(1-2):1-10 [11597743.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):40055-64 [11483611.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40545-54 [11504738.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 23):4143-51 [11739647.001]
  • [Cites] Mol Cell Neurosci. 2001 Dec;18(6):593-605 [11749036.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7398-407 [12196561.001]
  • [Cites] J Cell Biol. 2002 Sep 30;158(7):1299-309 [12356873.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):722-8 [12359212.001]
  • [Cites] Science. 2002 Oct 25;298(5594):770-6 [12399577.001]
  • [Cites] Trends Biochem Sci. 2003 Feb;28(2):106-12 [12575999.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2447-56 [12814376.001]
  • [Cites] Trends Immunol. 2003 Nov;24(11):610-7 [14596886.001]
  • [Cites] J Neurosci Res. 2003 Dec 1;74(5):744-53 [14635225.001]
  • [Cites] Biochem J. 2004 Jan 15;377(Pt 2):407-17 [14556650.001]
  • [Cites] Eur J Neurosci. 2004 Feb;19(3):659-66 [14984416.001]
  • [Cites] J Neurosci. 1991 Jun;11(6):1617-26 [1904480.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Biochemistry. 1992 Dec 15;31(49):12289-96 [1281423.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4029-33 [8171030.001]
  • [Cites] EMBO J. 1994 May 15;13(10):2322-30 [8194524.001]
  • [Cites] Neuroscience. 1995 Nov;69(1):83-8 [8637635.001]
  • [Cites] Neuroscience. 1995 Nov;69(1):89-98 [8637636.001]
  • [Cites] J Comp Neurol. 1996 Jul 8;370(4):465-78 [8807448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14002-8 [9391142.001]
  • [Cites] Acta Anat (Basel). 1998;162(2-3):75-84 [9831753.001]
  • [Cites] Biochem J. 1999 May 15;340 ( Pt 1):103-11 [10229664.001]
  • [Cites] J Neurocytol. 1998 Sep;27(9):695-703 [10447243.001]
  • [Cites] Nat Rev Immunol. 2005 Feb;5(2):136-48 [15688041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1939-44 [15677332.001]
  • [Cites] Physiology (Bethesda). 2005 Aug;20:218-24 [16024509.001]
  • [Cites] BMC Struct Biol. 2005;5:11 [15985154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17196-201 [16286650.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11 [16314869.001]
  • [Cites] Biol Psychiatry. 2006 Feb 1;59(3):244-51 [16140276.001]
  • [Cites] Neuroscience. 2006 Jun 30;140(2):597-606 [16600515.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7707-18 [16908530.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):22239-47 [17548356.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1855-67 [17644758.001]
  • [Cites] Brain Res. 2008 Mar 4;1197:1-12 [18241840.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):707-11 [18163405.001]
  • [Cites] Mol Vis. 2008;14:1623-30 [18776950.001]
  • [Cites] Stem Cells Dev. 2008 Aug;17(4):641-51 [18522499.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):167-70 [10655063.001]
  • [Cites] J Virol. 2000 Apr;74(8):3642-9 [10729140.001]
  • [Cites] Int J Dev Biol. 2000;44(6):725-31 [11061437.001]
  • (PMID = 19737934.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; K848JZ4886 / Cysteine
  • [Other-IDs] NLM/ PMC2797278
  •  go-up   go-down


3. Zhao J, Iida A, Ouchi Y, Satoh S, Watanabe S: M6a is expressed in the murine neural retina and regulates neurite extension. Mol Vis; 2008;14:1623-30
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] M6a is expressed in the murine neural retina and regulates neurite extension.
  • PURPOSE: Glycoprotein m6a (M6a) is a cell-surface glycoprotein that belongs to the myelin proteolipid protein family.
  • M6a is expressed mainly in the nervous system, and its expression and function in mammalian retina have not been described.
  • Using proteomics analysis of mouse retinal membrane fractions, we identified M6a as a retinal membrane protein that is strongly expressed at embryonic stages.
  • Our aim was to reveal the function of M6a in development of mouse retina in this work.
  • METHODS: Detailed expression pattern of M6a was examined by immunostaining using frozen sections of mouse retina obtained at various developmental stages.
  • For functional analysis of M6a in mouse retinal development, we performed retorovirus-mediated overexpression of M6a in mouse retinal explant culture.
  • RESULTS: M6a transcripts were strongly expressed in embryonic retina.
  • After completion of retinal differentiation, the level of expression decreased as mouse development progressed.
  • Immunohistochemistry showed that in the immature mouse retina, M6a was strongly expressed in the axons of retinal ganglion cells.
  • After birth, M6a expression was confined to the inner plexiform layer, and finally, to the inner and outer plexiform layers of adult mouse retina.
  • M6a expression was completely paralleled by that of the synaptic marker, synaptophysin.
  • Mouse retinal progenitor cells that overexpressed M6a following retrovirus-mediated gene transfer were subjected to in vitro explant or monolayer cultures.
  • The neurite outgrowth of M6a-overexpressing retinal cells was strikingly enhanced, although M6a did not affect differentiation and proliferation.
  • CONCLUSIONS: These results suggest that M6a plays a role in retinal development by regulating neurites, and it may also function to modulate synaptic activities in the adult retina.
  • [MeSH-minor] Animals. Biomarkers / metabolism. Cell Differentiation. Cell Lineage. Cell Proliferation. Gene Expression Regulation, Developmental. Mice. Mice, Inbred ICR. Mitosis. Protein Transport. Stem Cells / cytology. Stem Cells / metabolism. Synapses / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2007 Jan 1;301(1):141-54 [17069792.001]
  • [Cites] Dev Biol. 2006 Apr 1;292(1):265-76 [16499901.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):93-8 [10638760.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1063-6 [10871756.001]
  • [Cites] Trends Neurosci. 2002 Jan;25(1):32-8 [11801336.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7398-407 [12196561.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):722-8 [12359212.001]
  • [Cites] Brain Res Dev Brain Res. 2003 Oct 10;145(1):93-105 [14519497.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4513-21 [15121868.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] J Neurosci. 1991 Jun;11(6):1617-26 [1904480.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Dev Dyn. 1992 Aug;194(4):311-25 [1286213.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] Neuron. 1994 Mar;12(3):583-95 [7512350.001]
  • [Cites] J Comp Neurol. 1996 Jul 8;370(4):465-78 [8807448.001]
  • [Cites] Mech Dev. 1998 Aug;76(1-2):3-18 [9767078.001]
  • [Cites] J Neurosci Res. 1999 Jul 1;57(1):13-22 [10397631.001]
  • [Cites] J Neurocytol. 1998 Sep;27(9):695-703 [10447243.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4473-83 [16179606.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17196-201 [16286650.001]
  • [Cites] Biochem J. 2007 Nov 15;408(1):51-9 [17688421.001]
  • (PMID = 18776950.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Gpm6a protein, mouse; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2529470
  •  go-up   go-down


Advertisement
4. Cooper B, Fuchs E, Flügge G: Expression of the axonal membrane glycoprotein M6a is regulated by chronic stress. PLoS One; 2009;4(1):e3659

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the axonal membrane glycoprotein M6a is regulated by chronic stress.
  • The present study shows that chronic stress also regulates expression of M6a, a glycoprotein which is localised in axonal membranes.
  • We have previously demonstrated that M6a is a component of glutamatergic axons.
  • The present data reveal that it is the splice variant M6a-Ib, not M6a-Ia, which is strongly expressed in the brain.
  • Chronic stress in male rats (3 weeks daily restraint) has regional effects: quantitative in situ hybridization demonstrated that M6a-Ib mRNA in dentate gyrus granule neurons and in CA3 pyramidal neurons is downregulated, whereas M6a-Ib mRNA in the medial prefrontal cortex is upregulated by chronic stress.
  • Enhanced M6a-Ib expression in the medial prefrontal cortex (in areas prelimbic and infralimbic cortex) might be interpreted as a compensatory mechanism in response to changes in axonal projections from the hippocampus.
  • [MeSH-major] Axons / metabolism. Brain / metabolism. Gene Expression Regulation. Membrane Glycoproteins / genetics. Nerve Tissue Proteins / genetics. Stress, Physiological / physiology
  • [MeSH-minor] Animals. Down-Regulation. Gene Expression. In Situ Hybridization. Kidney / metabolism. Male. Neurons / metabolism. Protein Isoforms. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Restraint, Physical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 2000;97(2):253-66 [10799757.001]
  • [Cites] Behav Brain Res. 2008 Jun 26;190(1):1-13 [18384891.001]
  • [Cites] Mol Cell Neurosci. 2001 Dec;18(6):593-605 [11749036.001]
  • [Cites] Hippocampus. 2002;12(2):245-57 [12000121.001]
  • [Cites] Neurosci Biobehav Rev. 2002 May;26(3):321-52 [12034134.001]
  • [Cites] J Neuroendocrinol. 2002 Jun;14(6):499-505 [12047725.001]
  • [Cites] Eur J Neurosci. 2004 Feb;19(3):659-66 [14984416.001]
  • [Cites] Neuroscience. 2004;125(1):1-6 [15051139.001]
  • [Cites] BMC Genomics. 2003 Jul 29;4(1):31 [12885301.001]
  • [Cites] J Neurobiol. 2004 Aug;60(2):236-48 [15266654.001]
  • [Cites] Stress. 2004 Jun;7(2):131-43 [15512858.001]
  • [Cites] J Comp Neurol. 1977 Mar 1;172(1):49-84 [65364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5665-9 [2441390.001]
  • [Cites] Brain Res Bull. 1987 Dec;19(6):639-49 [2449937.001]
  • [Cites] Neuroscience. 1988 Feb;24(2):379-431 [2452377.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Brain Res. 1992 Aug 21;588(2):341-5 [1393587.001]
  • [Cites] J Neurosci. 1993 Sep;13(9):3839-47 [8396170.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] J Neurochem. 1993 Nov;61(5):1957-60 [7901339.001]
  • [Cites] Hippocampus. 1993;3 Spec No:33-44 [8287110.001]
  • [Cites] Neuroscience. 1995 Nov;69(1):83-8 [8637635.001]
  • [Cites] J Neurosci. 1996 May 15;16(10):3534-40 [8627386.001]
  • [Cites] J Comp Neurol. 1996 Jul 8;370(4):465-78 [8807448.001]
  • [Cites] J Comp Neurol. 1997 Jan 27;377(4):465-99 [9007187.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):154-60 [9056205.001]
  • [Cites] Nature. 1997 May 29;387(6632):497-500 [9168111.001]
  • [Cites] J Psychopharmacol. 1997;11(2):99-106 [9208373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14002-8 [9391142.001]
  • [Cites] Ann N Y Acad Sci. 1998 May 1;840:33-44 [9629234.001]
  • [Cites] J Neurosci. 1999 Apr 1;19(7):2834-40 [10087094.001]
  • [Cites] Am J Psychiatry. 1999 Jun;156(6):837-41 [10360120.001]
  • [Cites] J Neurosci Res. 2004 Dec 1;78(5):702-10 [15505804.001]
  • [Cites] J Comp Neurol. 2005 Nov 14;492(2):145-77 [16196030.001]
  • [Cites] Cereb Cortex. 2005 Nov;15(11):1714-22 [15703248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17196-201 [16286650.001]
  • [Cites] Biol Psychiatry. 2006 Feb 1;59(3):244-51 [16140276.001]
  • [Cites] Neuroscience. 2006 Jun 30;140(2):597-606 [16600515.001]
  • [Cites] Neuroscience. 2006 Sep 29;142(1):1-20 [16887277.001]
  • [Cites] Brain Res. 2007 Aug 3;1161:56-64 [17603026.001]
  • [Cites] Neural Plast. 2007;2007:46276 [18253468.001]
  • [Cites] Brain Res. 2008 Mar 4;1197:1-12 [18241840.001]
  • [Cites] Cell Mol Neurobiol. 2008 May;28(3):331-42 [18197473.001]
  • [Cites] J Neurobiol. 2001 Nov 15;49(3):245-53 [11745662.001]
  • (PMID = 19180239.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2629568
  •  go-up   go-down


5. McClintock-Treep SA, Horny HP, Sotlar K, Foucar MK, Reichard KK: KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation. J Clin Pathol; 2009 Dec;62(12):1147-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
  • A case of systemic mastocytosis associated with a clonal haematological non-mast cell lineage disease (SM-AHNMD), where the associated disease is acute erythroid leukaemia (erythroid/myeloid type), is reported.
  • Interestingly, molecular studies showed the KIT(D816V+) mutation not only in the mast cells, but also in the myeloid blast population and the leukaemic erythroid cells.
  • As is the case with most erythroid leukaemias, the patient had a very aggressive clinical course and died shortly after diagnosis.
  • It is believed that this is the first reported case of systemic mastocytosis with erythroid leukaemia where the KIT(D816V+) mutation was detected in all three cell types.
  • From a practice standpoint, this case illustrates the importance of definitively diagnosing the associated non-mast cell lineage disease due to its prognostic implications.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / genetics. Mastocytosis, Systemic / genetics. Mutation. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729359.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


6. Sakuragi Y, Kolter R: Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa. J Bacteriol; 2007 Jul;189(14):5383-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa.
  • Although QS regulation of swarming and DNA release has been shown to play important roles in biofilm development, regulation of genes directly involved in biosynthesis of biofilm matrix has not been described.
  • Here, transcription of the pel operon, essential for the production of a glucose-rich matrix exopolysaccharide, is shown to be greatly reduced in lasI and rhlI mutants.
  • Chemical complementation of the lasI mutant with 3-oxo-dodecanoyl homoserine lactone restores pel transcription to the wild-type level and biofilm formation ability.
  • These findings thus connect QS signaling and transcription of genes responsible for biofilm matrix biosynthesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechniques. 2000 Nov;29(5):948-50, 952 [11084852.001]
  • [Cites] Mol Microbiol. 2006 Dec;62(5):1264-77 [17059568.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6676-83 [11673439.001]
  • [Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]
  • [Cites] J Bacteriol. 2004 May;186(10):2936-45 [15126453.001]
  • [Cites] Annu Rev Microbiol. 1987;41:435-64 [3318676.001]
  • [Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]
  • [Cites] Mol Microbiol. 1998 Sep;29(6):1321-30 [9781871.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):745-54 [15525535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15833-9 [15505212.001]
  • [Cites] Trends Microbiol. 2005 Jan;13(1):20-6 [15639628.001]
  • [Cites] Trends Microbiol. 2005 Jan;13(1):27-33 [15639629.001]
  • [Cites] Microbiology. 2005 Mar;151(Pt 3):985-97 [15758243.001]
  • [Cites] Environ Microbiol. 2005 Apr;7(4):459-71 [15816912.001]
  • [Cites] RNA. 2005 Oct;11(10):1579-87 [16131593.001]
  • [Cites] Mol Microbiol. 2006 Feb;59(4):1114-28 [16430688.001]
  • [Cites] FEMS Microbiol Rev. 2006 Mar;30(2):274-91 [16472307.001]
  • [Cites] Int J Med Microbiol. 2006 Apr;296(2-3):73-81 [16476569.001]
  • [Cites] Cell Microbiol. 2006 Dec;8(12):1841-9 [17026480.001]
  • [Cites] J Bacteriol. 2001 Oct;183(19):5529-34 [11544214.001]
  • (PMID = 17496081.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM058213; United States / NIGMS NIH HHS / GM / GM58213
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins
  • [Other-IDs] NLM/ PMC1951888
  •  go-up   go-down


7. Wu DF, Koch T, Liang YJ, Stumm R, Schulz S, Schröder H, Höllt V: Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling. J Biol Chem; 2007 Jul 27;282(30):22239-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling.
  • Using a yeast two-hybrid screen, the neuronal membrane glycoprotein M6a, a member of the proteolipid protein family, was identified to be associated with the mu-opioid receptor (MOPr).
  • Bioluminescence resonance energy transfer and co-immunoprecipitation experiments confirmed that M6a interacts agonist-independently with MOPr in human embryonic kidney 293 cells co-expressing MOPr and M6a.
  • Co-expression of MOPr with M6a, but not with M6b or DM20, exists in many brain regions, further supporting a specific interaction between MOPr and M6a.
  • After opioid treatment M6a co-internalizes and then co-recycles with MOPr to cell surface in transfected human embryonic kidney 293 cells.
  • Moreover, the interaction of M6a and MOPr augments constitutive and agonist-dependent internalization as well as the recycling rate of mu-opioid receptors.
  • On the other hand, overexpression of a M6a-negative mutant prevents mu-opioid receptor endocytosis, demonstrating an essential role of M6a in receptor internalization.
  • In addition, we demonstrated the interaction of M6a with a number of other G protein-coupled receptors (GPCRs) such as the delta-opioid receptor, cannabinoid receptor CB1, and somatostatin receptor sst2A, suggesting that M6a might play a general role in the regulation of certain GPCRs.
  • Taken together, these data provide evidence that M6a may act as a scaffolding molecule in the regulation of GPCR endocytosis and intracellular trafficking.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548356.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Opioid, mu; 0 / Recombinant Proteins
  •  go-up   go-down


8. Liang YJ, Wu DF, Stumm R, Höllt V, Koch T: Membrane glycoprotein M6A promotes mu-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway. Cell Res; 2008 Jul;18(7):768-79
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane glycoprotein M6A promotes mu-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway.
  • The interaction of mu-opioid receptor (MOPr) with the neuronal membrane glycoprotein M6a is known to facilitate MOPr endocytosis in human embryonic kidney 293 (HEK293) cells.
  • To further study the role of M6a in the post-endocytotic sorting of MOPr, we investigated the agonist-induced co-internalization of MOPr and M6a and protein targeting after internalization in HEK293 cells that co-expressed HA-tagged MOPr and Myc-tagged M6a.
  • We found that M6a, MOPr, and Rab 11, a marker for recycling endosomes, co-localized in endocytotic vesicles, indicating that MOPr and M6a are primarily targeted to recycling endosomes after endocytosis.
  • Furthermore, co-expression of M6a augmented the post-endocytotic sorting of delta-opioid receptors into the recycling pathway, indicating that M6a might have a more general role in opioid receptor post-endocytotic sorting.
  • The enhanced post-endocytotic sorting of MOPr into the recycling pathway was accompanied by a decrease in agonist-induced receptor down-regulation of M6a in co-expressing cells.
  • We tested the physiological relevance of these findings in primary cultures of cortical neurons and found that co-expression of M6a markedly increased the translocation of MOPrs from the plasma membrane to intracellular vesicles at steady state and significantly enhanced both constitutive and agonist-induced receptor endocytosis.
  • In conclusion, our results strongly indicate that M6a modulates MOPr endocytosis and post-endocytotic sorting and has an important role in receptor regulation.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574501.001).
  • [ISSN] 1748-7838
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / OPRM1 protein, human; 0 / Receptors, Opioid, mu; EC 2.1.1.- / Methyltransferases; EC 2.1.1.62 / METTL3 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins; EC 3.6.1.- / rab11 protein
  •  go-up   go-down


9. Gluzman DF, Nadgornaya VA, Sklyarenko LM, Ivanovskaya TS, Poludnenko LY, Ukrainskaya NI: Immunocytochemical markers in acute leukaemias diagnosis. Exp Oncol; 2010 Sep;32(3):195-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical markers in acute leukaemias diagnosis.
  • The study included 1742 patients with acute myeloblastic leukaemias (AML) and acute lymphoblastic leukaemias (ALL), Kyiv city residents and patients from 20 regions of Ukraine.
  • Bone marrow and blood smears were sent at diagnosis to Reference Center.
  • Different types of AML were defined by the expression of the cell surface and cytoplasmic antigens.
  • Immunocytochemical study was required especially in diagnosing of AML with minimal differentiation, acute megakaryoblastic leukaemia, acute erythroid leukaemia and acute leukaemias of ambiguous lineage.
  • Acute lymphoblastic leukaemias was broadly classified into B-lineage and T-lineage ALL.
  • Immunocytochemical examination was required to diagnose AL of ambiguous lineage with no clear evidence of lineage differentiation (acute undifferentiated leukaemia) or those with blasts that express markers of more than one lineage (mixed phenotype acute leukaemias).
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / immunology. Humans. Immunohistochemistry. Immunophenotyping. Lymphocyte Subsets / immunology. Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21403617.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. van Gijn J, Gijselhart J: [Professor Pel and 'glandular fever']. Ned Tijdschr Geneeskd; 2009;153:A1215
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Professor Pel and 'glandular fever'].
  • [Transliterated title] Professor Pel en 'klierkoorts'.
  • Pieter Klaesz Pel (1852-1919) was professor of internal medicine at the University of Amsterdam, for more than 35 years.
  • It is contested whether the patients in question had Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051175.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Biography; English Abstract; Historical Article; Journal Article; Portraits
  • [Publication-country] Netherlands
  • [Personal-name-as-subject] Pel PK
  •  go-up   go-down


11. Sharma P, Dhingra KK, Roy S, Singh T: An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia. J Pediatr Hematol Oncol; 2009 Mar;31(3):220-1
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
  • The case of a 12 yr old female with bcr-abl positive chronic myeloid leukemia who subsequently developed a fatal AML-M6b (pure erythroleukemia) blast crisis is presented.
  • The case is unique for its rarity of occurrence and for the striking resemblance that the circulating proerythroblasts showed to the giant cells characteristically seen in Parvovirus B19-induced acute pure red cell aplasia.
  • This is, to the best of our knowledge, the first description of such cells in a blast crisis of chronic myeloid leukemia.
  • [MeSH-major] Blast Crisis / pathology. Erythroblasts / pathology. Leukemia, Erythroblastic, Acute / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262253.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


12. Matsumoto T, Matsubara M, Oana K, Kasuga E, Suzuki T, Hidaka E, Shigemura T, Yamauchi K, Honda T, Ota H, Kawakami Y: First case of bacteremia due to chromosome-encoded CfxA3-beta-lactamase-producing Capnocytophaga sputigena in a pediatric patient with acute erythroblastic leukemia. Eur J Med Res; 2008 Mar 31;13(3):133-5
Genetic Alliance. consumer health - Acute Erythroblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First case of bacteremia due to chromosome-encoded CfxA3-beta-lactamase-producing Capnocytophaga sputigena in a pediatric patient with acute erythroblastic leukemia.
  • Bacteremia due to Capnocytophaga sputigena occurred in a 4-year and 9-month-old Japanese girl patient with acute erythroblastic leukemia in Shinshu University Hospital, Japan.
  • The causative Capnocytophaga sputigena isolate was found to be a beta-lactamase-producer demonstrating to possess cfxA3 gene.
  • The gene responsible for the production of CfxA3-beta-lactamase was proved to be chromosome-encoded, by means of southern hybridization analysis.
  • [MeSH-major] Bacteremia / microbiology. Capnocytophaga / isolation & purification. Chromosomes, Bacterial. Leukemia, Erythroblastic, Acute / complications. beta-Lactamases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499560.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; EC 3.5.2.6 / beta-Lactamases
  •  go-up   go-down


13. Cooper B, Werner HB, Flügge G: Glycoprotein M6a is present in glutamatergic axons in adult rat forebrain and cerebellum. Brain Res; 2008 Mar 4;1197:1-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycoprotein M6a is present in glutamatergic axons in adult rat forebrain and cerebellum.
  • Glycoprotein M6a is a neuronally expressed member of the proteolipid protein (PLP) family of tetraspans.
  • In vitro studies suggested a potential role in neurite outgrowth and spine formation and previous investigations have identified M6a as a stress-regulated gene.
  • To investigate whether the distribution of M6a correlates with neuronal structures susceptible to alterations in response to stress, we localized M6a expression in neurons of hippocampal formation, prefrontal cortex and cerebellum using in situ hybridization and confocal immunofluorescence microscopy.
  • In situ hybridization confirmed that M6a is expressed in dentate gyrus and cerebellar granule neurons and in hippocampal and cortical pyramidal neurons.
  • Confocal microscopy localized M6a immunoreactivity to distinct sites within axonal membranes, but not in dendrites or neuronal somata.
  • Moreover, M6a colocalized with synaptic markers of glutamatergic, but not GABAergic nerve terminals.
  • M6a expression in the adult brain is particularly strong in unmyelinated axonal fibers, i.e. cerebellar parallel and hippocampal mossy fibers.
  • In contrast, myelinated axons exhibit only minimal M6a immunoreactivity localized exclusively to terminal regions.
  • The present neuroanatomical data demonstrate that M6a is an axonal component of glutamatergic neurons and that it is localized to distinct sites of the axonal plasma membrane of pyramidal and granule cells.
  • [MeSH-minor] Animals. Fluorescent Antibody Technique. Gene Expression. Glutamine. In Situ Hybridization. Male. Microscopy, Confocal. RNA, Messenger / analysis. Rats. Rats, Sprague-Dawley. Vesicular Glutamate Transport Proteins / metabolism

  • Hazardous Substances Data Bank. Glutamine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241840.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Vesicular Glutamate Transport Proteins; 0RH81L854J / Glutamine
  •  go-up   go-down


14. Honda Y, Manabe A, Tsuchida M, Zaike Y, Masunaga A, Inoue M, Kobayashi R, Ohtsuka Y, Kikuchi A, Nakahata T, MDS Committee, the Japanese Society of Pediatric Hematology: Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children. Int J Hematol; 2008 Dec;88(5):524-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children.
  • The distinction between RAEB, RAEB-T and AML M6a is difficult when erythroblasts in the bone marrow (BM) exceed 50%.
  • We analyzed 19 children (2 RAEB, 13 RAEB-T and 4 AML M6a) enrolled in a prospective pathological central review in Japan and divided them into two groups according to the myeloblasts percentage among non-erythroid cells in BM: group A (n = 8), 5-19% myeloblasts; group B (n = 11), 20% or more myeloblasts.
  • Six with group A and seven with group B treated with AML type chemotherapy achieved complete remission.
  • Five with group A and seven with group B undergoing SCT are alive at a median of 3 years after diagnosis.
  • Erythroblast-rich RAEB and AML M6a in children have similar characteristics and may belong to a single disease entity.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / pathology. Erythroblasts / pathology. Granulocyte Precursor Cells / pathology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Japan. Leukocyte Count. Male. Prospective Studies. Remission Induction. Stem Cell Transplantation. Time Factors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951200.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


15. Knoblauch RE, Thompson CB: Targeting tumor metabolism: biguanides as anti-neoplastic agents. J Clin Oncol; 2009 May 20;27(15_suppl):e14592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14592 Background: During the process of malignant transformation, the tumor cell adopts a new form of metabolism, characterized by aerobic glycolysis and altered TCA cycle flux, that enable it to meet the energetic and biosynthetic demands of proliferation.
  • METHODS: We have characterized the proliferative and metabolic effects of phenformin, a member of the biguanide family of compounds used in the treatment of diabetes, on the bcr-abl expressing K562 erythroleukemia cell line, and compared the resulting phenotype to those of imatinib and rapamycin, two targeted agents used in the treatment of malignant disease.
  • Phenformin treatment eliminated the mitochondrial contribution to anabolic metabolism, through inhibition of Complex I of the Electron Transport Chain, as demonstrated by reduced oxygen consumption and intracellular ATP levels.
  • CONCLUSIONS: Our results confirm the importance of metabolism to the proliferation of malignant cells, thereby validating anabolic metabolism's potential for therapeutic intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963742.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Speake G, Klinowska T, Hickinson M, Marshall G, Smith P, Vincent J, Anderton J, Gray N, Smith I, Ogilvie D: Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile. J Clin Oncol; 2009 May 20;27(15_suppl):11072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile.
  • Characterization of a novel tyrosine kinase inhibitor with a potent and balanced profile against EGFR, HER2 (erbB2), and HER3 (erbB3) has been carried out.
  • These assays have provided unique insights into the pharmacology of these drugs that result from the varying levels of HER and their associated ligands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Arumugam PI, Scholes J, Perelman N, Xia P, Yee JK, Malik P: Improved Human β-globin Expression from Self-inactivating Lentiviral Vectors Carrying the Chicken Hypersensitive Site-4 (cHS4) Insulator Element. Mol Ther; 2007 Oct;15(10):1863-1871

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Effective gene therapy for β-thalassemia major (β-TM) requires consistent, high expression of human β-globin (hβ-globin) in red blood cells (RBCs).
  • Several groups have now shown that lentiviral (LV) vectors stably transmit the hβ/hγ-globin genes and large elements of the locus control region, resulting in correction of the murine thalassemia intermedia (TI) phenotype and survival of mice with the TM phenotype.
  • We observed a consistent twofold-higher hβ expression from insulated vectors in single-copy mouse erythroleukemia cell clones, an increase that resulted from reduced position effect variegation (PEV) and increased probability of expression from individual integrants.
  • These studies have important implications for vector design for clinical trials for gene therapy for hemoglobinopathies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182916.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Brocco MA, Fernández ME, Frasch AC: Filopodial protrusions induced by glycoprotein M6a exhibit high motility and aids synapse formation. Eur J Neurosci; 2010 Jan;31(2):195-202

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Filopodial protrusions induced by glycoprotein M6a exhibit high motility and aids synapse formation.
  • M6a is a neuronal membrane glycoprotein whose expression diminishes during chronic stress.
  • M6a overexpression in rat primary hippocampal neurons induces the formation of filopodial protrusions that could be spine precursors.
  • As the filopodium and spine motility has been associated with synaptogenesis, we analysed the motility of M6a-induced protrusions by time-lapse imaging.
  • Our data demonstrate that the motile protrusions formed by the neurons overexpressing M6a were more abundant and moved faster than those formed in control cells.
  • When different putative M6a phosphorylation sites were mutated, the neurons transfected with a mutant lacking intracellular phosphorylation sites bore filopodia, but these protrusions did not move as fast as those formed by cells overexpressing wild-type M6a.
  • This suggests a role for M6a phosphorylation state in filopodium motility.
  • Furthermore, we show that M6a-induced protrusions could be stabilized upon contact with presynaptic region.
  • The behavior of filopodia from M6a-overexpressing cells and control cells was alike.
  • Thus, M6a-induced protrusions may be spine precursors that move to reach presynaptic membrane.
  • We suggest that M6a is a key molecule for spine formation during development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074218.001).
  • [ISSN] 1460-9568
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


19. Huang G, Dong R, Allen R, Davis EL, Baum TJ, Hussey RS: Developmental expression and molecular analysis of two Meloidogyne incognita pectate lyase genes. Int J Parasitol; 2005 May;35(6):685-92
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental expression and molecular analysis of two Meloidogyne incognita pectate lyase genes.
  • Two cDNAs (designated Mi-pel-1 and Mi-pel-2) encoding pectate lyases were isolated from the root-knot nematode, Meloidogyne incognita, oesophageal gland-cell subtractive cDNA libraries, and the corresponding genomic DNAs were subsequently cloned.
  • Southern blot analyses revealed that homologues to these pectate lyase genes were broadly distributed in Meloidogyne species, and present as members of a small multigene family.
  • Mi-pel-1 and Mi-pel-2 encoded, respectively, predicted proteins of 271 and 280 amino acids, each of which was preceded by a signal peptide for secretion.
  • Interestingly, these pectate lyases showed diversity at the amino acid level, with only 31% identity and 49% similarity.
  • These pectate lyases were classified into the same family of pectate lyases with those of other phytoparasitic nematodes that contain four conserved regions characteristic of the class III pectate lyases of microbes.
  • In situ mRNA hybridisation analyses showed the transcripts of Mi-pel-1 and Mi-pel-2 accumulated exclusively within the subventral oesophageal gland cells of M. incognita.
  • These results indicated that these pectate lyases, like cellulases, could be secreted into plant tissues to facilitate the penetration and intercellular migration of M. incognita during the early stages of plant parasitism.
  • [MeSH-major] Gene Expression Regulation, Developmental / genetics. Polysaccharide-Lyases / genetics. Tylenchoidea / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Blotting, Southern / methods. Cloning, Molecular / methods. DNA, Circular / genetics. DNA, Helminth / genetics. Genes, Helminth / genetics. In Situ Hybridization / methods. Molecular Sequence Data. Phylogeny. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862581.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF527788/ AY327873/ AY515702/ AY515703
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Circular; 0 / DNA, Helminth; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


20. Fjorback AW, Müller HK, Wiborg O: Membrane glycoprotein M6B interacts with the human serotonin transporter. J Mol Neurosci; 2009 Mar;37(3):191-200
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane glycoprotein M6B interacts with the human serotonin transporter.
  • In the present study, using the yeast two-hybrid system, we identified the membrane glycoprotein M6B as a binding partner of SERT.
  • M6B belongs to a proteolipid protein family, which is expressed in neurons and in oligodendrocytes in the brain.
  • The co-expression of SERT with M6B results in a significant decrease in SERT-mediated serotonin uptake caused by a down-regulation of SERT surface expression.
  • Furthermore, we find, using confocal microscopy, that M6B co-localizes with SERT when transiently expressed in HEK-MSR-293 cells and when endogenously expressed in RN46A cells.
  • Taken together, our data suggest that M6B regulates the serotonin uptake by affecting cellular trafficking of the serotonin transporter.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581270.001).
  • [ISSN] 0895-8696
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPM6A protein, human; 0 / GPM6B protein, human; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Serotonin Plasma Membrane Transport Proteins; 333DO1RDJY / Serotonin
  •  go-up   go-down


21. Alfonso J, Fernández ME, Cooper B, Flugge G, Frasch AC: The stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation. Proc Natl Acad Sci U S A; 2005 Nov 22;102(47):17196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation.
  • We have recently identified the glycoprotein M6a as a stress-responsive gene in the hippocampal formation.
  • This gene is down-regulated in the hippocampus of both socially and physically stressed animals, and this effect can be reversed by antidepressant treatment.
  • In the present work, we analyzed the biological function of the M6a protein.
  • Immunohistochemistry showed that the M6a protein is abundant in all hippocampal subregions, and subcellular analysis in primary hippocampal neurons revealed its presence in membrane protrusions (filopodia/spines).
  • Transfection experiments revealed that M6a overexpression induces neurite formation and increases filopodia density in hippocampal neurons.
  • M6a knockdown with small interference RNA methodology showed that M6a low-expressing neurons display decreased filopodia number and a lower density of synaptophysin clusters.
  • Taken together, our findings indicate that M6a plays an important role in neurite/filopodium outgrowth and synapse formation.
  • Therefore, reduced M6a expression might be responsible for the morphological alterations found in the hippocampus of chronically stressed animals.
  • Potential mechanisms that might explain the biological effects of M6a are discussed.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 1996 Jul;17(1):91-102 [8755481.001]
  • [Cites] J Neurosci. 1996 May 15;16(10):3534-40 [8627386.001]
  • [Cites] Science. 1998 Jan 23;279(5350):509-14 [9438836.001]
  • [Cites] Psychopharmacology (Berl). 1997 Dec;134(4):319-29 [9452163.001]
  • [Cites] J Neurosci. 1998 Nov 1;18(21):8900-11 [9786995.001]
  • [Cites] Annu Rev Neurosci. 1999;22:105-22 [10202533.001]
  • [Cites] Am J Psychiatry. 1999 Jun;156(6):837-41 [10360120.001]
  • [Cites] J Cell Biol. 1999 Jun 14;145(6):1265-75 [10366598.001]
  • [Cites] J Neurocytol. 1998 Sep;27(9):695-703 [10447243.001]
  • [Cites] Prog Brain Res. 2005;147:29-37 [15581695.001]
  • [Cites] Neuroscience. 2005;131(1):43-54 [15680690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13438-43 [10557339.001]
  • [Cites] Neuroscience. 2000;97(2):253-66 [10799757.001]
  • [Cites] Brain Res. 2000 Oct 13;880(1-2):147-58 [11032999.001]
  • [Cites] Biol Psychiatry. 2000 Oct 15;48(8):721-31 [11063969.001]
  • [Cites] Hippocampus. 2000;10(5):582-6 [11075828.001]
  • [Cites] Nat Rev Neurosci. 2000 Dec;1(3):173-80 [11257905.001]
  • [Cites] J Neurosci. 2001 Jul 15;21(14):5169-81 [11438592.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):6105-14 [11487634.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):6292-7 [11487652.001]
  • [Cites] Pharmacol Biochem Behav. 2002 Aug;73(1):247-58 [12076743.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7398-407 [12196561.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):722-8 [12359212.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:601-35 [12142283.001]
  • [Cites] Hippocampus. 2002;12(5):585-91 [12440574.001]
  • [Cites] J Neurosci. 2003 Jan 15;23(2):659-65 [12533625.001]
  • [Cites] Neuron. 2003 Jan 23;37(2):263-74 [12546821.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2447-56 [12814376.001]
  • [Cites] Rev Neurosci. 2003;14(3):233-40 [14513866.001]
  • [Cites] Neuron. 2003 Oct 9;40(2):243-64 [14556707.001]
  • [Cites] J Neurosci Res. 2003 Dec 1;74(5):744-53 [14635225.001]
  • [Cites] Eur J Neurosci. 2004 Feb;19(3):659-66 [14984416.001]
  • [Cites] Curr Opin Pharmacol. 2004 Feb;4(1):58-64 [15018840.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):321-34 [15473970.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):782-8 [15483599.001]
  • [Cites] J Neurosci. 1991 Jun;11(6):1617-26 [1904480.001]
  • [Cites] J Neurobiol. 1992 Feb;23(1):71-88 [1564456.001]
  • [Cites] Brain Res. 1992 Aug 21;588(2):341-5 [1393587.001]
  • [Cites] Neuron. 1993 Sep;11(3):423-31 [8398137.001]
  • [Cites] Arch Gen Psychiatry. 1997 Jul;54(7):597-606 [9236543.001]
  • (PMID = 16286650.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC1287971
  •  go-up   go-down


22. Richetta A, Amoruso GF, Ascoli V, Natale ME, Carboni V, Carlomagno V, Pezza M, Cimillo M, Maiani E, Mattozzi C, Calvieri S: PEL, Kaposi's sarcoma HHV8+ and idiopathic T-lymphocitopenia CD4+. Clin Ter; 2007 Mar-Apr;158(2):151-5
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEL, Kaposi's sarcoma HHV8+ and idiopathic T-lymphocitopenia CD4+.
  • We described a case report of a 36-year-old woman with a 10-year-history of idiopathic CD4+ T-lymphocitopenia and Kaposi's sarcoma HHV8+ who developed recurrent pleural effusion.
  • Laboratory and instrumental tests with morphologic, immunophenotypic and molecular analysis of pleural sediment suggest us the diagnosis of primary effusion lymphoma (PEL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566517.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, Henry D, Harrington WJ Jr, Damania BA, Dittmer DP: Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood; 2007 Mar 1;109(5):2165-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.
  • Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV).
  • We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model;.
  • (2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated in PEL;.
  • This validates sirolimus as a new treatment option for PEL.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1393-400 [10555008.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] J Infect Dis. 2000 Dec;182(6):1809-10 [11069261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41 [11134523.001]
  • [Cites] Clin Infect Dis. 2001 May 15;32(10):1502-5 [11317254.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1758-64 [11410517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 [11504907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] J Infect. 2001 Oct;43(3):195-9 [11798259.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13907-17 [11847216.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7291-7 [12499272.001]
  • [Cites] J Virol. 2003 May;77(10):5759-73 [12719569.001]
  • [Cites] Nat Med. 2003 May;9(5):554-61 [12692543.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4472-80 [12907620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):343-8 [14667501.001]
  • [Cites] J Virol. 2004 Feb;78(4):1918-27 [14747556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Nat Rev Microbiol. 2004 Aug;2(8):656-68 [15263900.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] Cancer Res. 1988 Feb 1;48(3):589-601 [3335022.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2475-81 [9516148.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Transplantation. 1999 Apr 27;67(8):1200-1 [10232577.001]
  • [Cites] Transplantation. 1999 May 15;67(9):1236-42 [10342315.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Virol. 1999 Jul;73(7):6136-40 [10364372.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1122-8 [15467718.001]
  • [Cites] Trends Biochem Sci. 2005 Jan;30(1):35-42 [15653324.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3102-8 [15837766.001]
  • [Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):179-83 [16169463.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):168-74 [16397229.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):683-5 [15220917.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Eur Cytokine Netw. 1999 Dec;10(4):501-8 [10586116.001]
  • (PMID = 17082322.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL083469; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA096500; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIAID NIH HHS / AI / AI057157; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA098110; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA112935; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA098110; United States / NHLBI NIH HHS / HL / R01 HL083469; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NIAID NIH HHS / AI / U54 AI057157; United States / NCI NIH HHS / CA / R01 CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1801055
  •  go-up   go-down


24. Vasseur P, Vallet-Gely I, Soscia C, Genin S, Filloux A: The pel genes of the Pseudomonas aeruginosa PAK strain are involved at early and late stages of biofilm formation. Microbiology; 2005 Mar;151(Pt 3):985-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pel genes of the Pseudomonas aeruginosa PAK strain are involved at early and late stages of biofilm formation.
  • Biofilm-deficient P. aeruginosa PAK strains affected in a seven-gene cluster called pel were characterized.
  • The pel genes encode proteins with similarity to components involved in polysaccharide biogenesis, of which PelF is a putative glycosyltransferase.
  • The pel genes were previously identified in the P. aeruginosa PA14 strain as required for the production of a glucose-rich matrix material involved in the formation of a thick pellicle and resistant biofilm.
  • However, in PA14, the pel mutants have no clear phenotype in the initiation phase of attachment.
  • It was shown that pel mutations in the PAK strain had little influence on biofilm initiation but, as in PA14, appeared to generate the least robust and mature biofilms.
  • Strikingly, by constructing pel mutants in a non-piliated P. aeruginosa PAK strain, an unexpected effect of the pel mutation in the early phase of biofilm formation was discovered, since it was observed that these mutants were severely defective in the attachment process on solid surfaces.
  • The pel gene cluster is conserved in other Gram-negative bacteria, and mutation in a Ralstonia solanacearum pelG homologue, ragG, led to an adherence defect.
  • [MeSH-minor] Bacterial Adhesion. Culture Media. DNA Transposable Elements. Gene Expression Regulation, Bacterial. Glycosyltransferases / genetics. Glycosyltransferases / metabolism. Hydrophobic and Hydrophilic Interactions. Multigene Family. Mutation. Polysaccharides, Bacterial / genetics. Polysaccharides, Bacterial / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758243.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 0 / DNA Transposable Elements; 0 / Polysaccharides, Bacterial; EC 2.4.- / Glycosyltransferases
  •  go-up   go-down


25. Ueda A, Wood TK: Connecting quorum sensing, c-di-GMP, pel polysaccharide, and biofilm formation in Pseudomonas aeruginosa through tyrosine phosphatase TpbA (PA3885). PLoS Pathog; 2009 Jun;5(6):e1000483
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connecting quorum sensing, c-di-GMP, pel polysaccharide, and biofilm formation in Pseudomonas aeruginosa through tyrosine phosphatase TpbA (PA3885).
  • This screen identified the PA3885 mutant, which had 147-fold more biofilm than the wild-type strain.
  • Whole transcriptome analysis showed that loss of PA3885 activated expression of the pel locus, an operon that encodes for the synthesis of extracellular matrix polysaccharide.
  • Genetic screening identified that loss of PelABDEG and the PA1120 protein (which contains a GGDEF-motif) suppressed the phenotypes of the PA3885 mutant, suggesting that the function of the PA3885 protein is to regulate 3,5-cyclic diguanylic acid (c-di-GMP) concentrations as a phosphatase since c-di-GMP enhances biofilm formation by activating PelD, and c-di-GMP inhibits swarming.
  • Loss of PA3885 protein increased cellular c-di-GMP concentrations; hence, PA3885 protein is a negative regulator of c-di-GMP production.
  • Las-mediated quorum sensing positively regulates expression of the PA3885 gene.
  • These results show that the PA3885 protein responds to AHL signals and likely dephosphorylates PA1120, which leads to reduced c-di-GMP production.
  • This inhibits matrix exopolysaccharide formation, which leads to reduced biofilm formation; hence, we provide a mechanism for quorum sensing control of biofilm formation through the pel locus and suggest PA3885 should be named TpbA for tyrosine phosphatase related to biofilm formation and PA1120 should be TpbB.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 2007 Nov;189(22):8154-64 [17586642.001]
  • [Cites] Curr Opin Microbiol. 2007 Dec;10(6):644-8 [17981495.001]
  • [Cites] J Bacteriol. 2008 Apr;190(8):2671-9 [18245294.001]
  • [Cites] J Biol Chem. 2008 Apr 11;283(15):9933-44 [18256026.001]
  • [Cites] Appl Microbiol Biotechnol. 2008 Jul;79(5):843-58 [18481058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13904-9 [10570171.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):959-64 [10984043.001]
  • [Cites] J Bacteriol. 2000 Nov;182(21):5990-6 [11029417.001]
  • [Cites] Trends Microbiol. 2000 Nov;8(11):498-504 [11121759.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(3):809-21 [11929534.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):155-66 [11932228.001]
  • [Cites] Mol Microbiol. 2002 Oct;46(2):571-86 [12406230.001]
  • [Cites] J Bacteriol. 2003 Feb;185(3):1027-36 [12533479.001]
  • [Cites] J Bacteriol. 2003 Apr;185(7):2080-95 [12644477.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13627-32 [12556522.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14429-41 [12562757.001]
  • [Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]
  • [Cites] Arch Microbiol. 2004 Mar;181(3):171-81 [14745484.001]
  • [Cites] Appl Microbiol Biotechnol. 2004 May;64(4):515-24 [14727089.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4466-75 [15231778.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(4):1075-87 [15306012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Apr;76(4):1648-52 [377280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7347-51 [7012838.001]
  • [Cites] J Bacteriol. 1986 Mar;165(3):1002-10 [3005231.001]
  • [Cites] J Biol Chem. 1990 Nov 5;265(31):18933-43 [2172238.001]
  • [Cites] Methods Enzymol. 1991;201:477-82 [1943774.001]
  • [Cites] Science. 1993 May 21;260(5111):1127-30 [8493556.001]
  • [Cites] Annu Rev Microbiol. 1993;47:597-626 [8257110.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):654-9 [7836299.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5910-4 [7597052.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6424-8 [7604006.001]
  • [Cites] Mol Microbiol. 2008 Jul;69(2):376-89 [18485075.001]
  • [Cites] Mol Microbiol. 2008 Sep;69(5):1153-64 [18573179.001]
  • [Cites] J Mol Biol. 2008 Nov 7;383(2):414-23 [18775435.001]
  • [Cites] Trends Microbiol. 2008 Oct;16(10):496-506 [18775660.001]
  • [Cites] J Bacteriol. 2009 Jan;191(1):169-77 [18952786.001]
  • [Cites] Microb Biotechnol. 2009 Jan;2(1):62-74 [21261882.001]
  • [Cites] Proteins. 1991;11(2):95-110 [1946347.001]
  • [Cites] Biochem J. 1995 Nov 1;311 ( Pt 3):921-7 [7487952.001]
  • [Cites] J Biochem. 1996 Dec;120(6):1055-63 [9010748.001]
  • [Cites] J Bacteriol. 1997 May;179(10):3127-32 [9150205.001]
  • [Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]
  • [Cites] Bioinformatics. 1998;14(4):378-9 [9632836.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 1998;27:133-64 [9646865.001]
  • [Cites] Mol Microbiol. 1998 Oct;30(2):285-93 [9791174.001]
  • [Cites] Mol Microbiol. 1998 Oct;30(2):295-304 [9791175.001]
  • [Cites] J Bacteriol. 1998 Dec;180(23):6384-8 [9829950.001]
  • [Cites] Biotechnol Bioeng. 2004 Dec 5;88(5):630-42 [15470704.001]
  • [Cites] Mol Microbiol. 2005 Jan;55(2):368-80 [15659157.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):1954-63 [15784535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14422-7 [16186483.001]
  • [Cites] J Microbiol. 2005 Oct;43(5):443-50 [16273037.001]
  • [Cites] J Bacteriol. 2006 Jan;188(1):305-16 [16352847.001]
  • [Cites] J Mol Microbiol Biotechnol. 2005;9(3-4):125-31 [16415586.001]
  • [Cites] Int J Med Microbiol. 2006 Apr;296(2-3):83-91 [16483840.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):8090-9 [16418169.001]
  • [Cites] Curr Opin Microbiol. 2006 Apr;9(2):218-28 [16530465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2833-8 [16477005.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2839-44 [16477007.001]
  • [Cites] Microbiology. 2006 Jun;152(Pt 6):1679-86 [16735731.001]
  • [Cites] DNA Res. 2005;12(5):291-9 [16769691.001]
  • [Cites] Appl Environ Microbiol. 2006 Jul;72(7):5027-36 [16820502.001]
  • [Cites] J Bacteriol. 2007 May;189(9):3603-12 [17337585.001]
  • [Cites] J Bacteriol. 2007 Jul;189(14):5383-6 [17496081.001]
  • [Cites] Nat Cell Biol. 2007 Jul;9(7):797-803 [17558395.001]
  • [Cites] J Bacteriol. 2007 Sep;189(18):6695-703 [17631636.001]
  • [Cites] Environ Microbiol. 2007 Oct;9(10):2475-85 [17803773.001]
  • [Cites] Mol Microbiol. 2007 Sep;65(6):1474-84 [17824927.001]
  • [Cites] J Bacteriol. 2007 Nov;189(22):8165-78 [17586641.001]
  • (PMID = 19543378.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB003872
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Bacterial Proteins; 0 / Glycolipids; 0 / Polysaccharides, Bacterial; 0 / rhamnolipid; 42HK56048U / Tyrosine; 61093-23-0 / bis(3',5')-cyclic diguanylic acid; EC 3.1.3.48 / Protein Tyrosine Phosphatases; H2D2X058MU / Cyclic GMP
  • [Other-IDs] NLM/ PMC2691606
  •  go-up   go-down


26. Feng L, Musto CJ, Kemling JW, Lim SH, Suslick KS: A colorimetric sensor array for identification of toxic gases below permissible exposure limits. Chem Commun (Camb); 2010 Mar 28;46(12):2037-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A colorimetric sensor array for identification of toxic gases below permissible exposure limits.
  • A colorimetric sensor array has been developed for the rapid and sensitive detection of 20 toxic industrial chemicals (TICs) at their PELs (permissible exposure limits).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Mater. 2003 Jan;2(1):19-24 [12652667.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):710-3 [10963592.001]
  • [Cites] Anal Chem. 2009 Aug 1;81(15):6526-33 [20337402.001]
  • [Cites] Anal Chem. 2009 Jul 1;81(13):5281-90 [19563211.001]
  • [Cites] Org Lett. 2008 Oct 16;10(20):4405-8 [18783231.001]
  • [Cites] Nat Chem. 2009 Oct;1(7):562-7 [20160982.001]
  • [Cites] Anal Chem. 2006 Jun 1;78(11):3591-600 [16737212.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jul 18;44(29):4528-32 [16003792.001]
  • [Cites] MRS Bull. 2004 Oct;29(10):720-5 [15991401.001]
  • [Cites] Acc Chem Res. 2004 Sep;37(9):663-72 [15379582.001]
  • [Cites] J Org Chem. 2007 Feb 2;72(3):687-99 [17253783.001]
  • (PMID = 20221484.001).
  • [ISSN] 1364-548X
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / U01 ES016011; United States / NIEHS NIH HHS / ES / U01 ES016011-04; United States / NIEHS NIH HHS / ES / U01ES016011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gases
  • [Other-IDs] NLM/ NIHMS229286; NLM/ PMC2976522
  •  go-up   go-down


27. Arguello M, Paz S, Hernandez E, Corriveau-Bourque C, Fawaz LM, Hiscott J, Lin R: Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production. J Immunol; 2006 Jun 1;176(11):7051-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production.
  • Primary effusion lymphoma (PEL) is a herpesvirus-8-associated lymphoproliferative disease characterized by migration of tumor cells to serous body cavities.
  • PEL cells originate from postgerminal center B cells and share a remarkable alteration in B cell transcription factor expression and/or activation with classical Hodgkin's disease cells.
  • Comparative analysis of gene expression by cDNA microarray of BCBL-1 cells (PEL), L-428 (classical Hodgkin's disease), and BJAB cells revealed a subset of genes that were differentially expressed in BCBL-1 cells.
  • Among these, four genes involved in cell migration and chemotaxis were strongly up-regulated in PEL cells: leukotriene A4 (LTA4) hydrolase (LTA4H), IL-16, thrombospondin-1 (TSP-1), and selectin-P ligand (PSGL-1).
  • Up-regulation of LTA4H was investigated at the transcriptional level.
  • Formation of a specific DNA-protein complex in this region was confirmed by EMSA.
  • [MeSH-minor] Cell Line, Tumor. Enzyme Activation / genetics. Gene Expression Profiling. Hodgkin Disease / genetics. Humans. Inflammation / genetics. Inflammation / immunology. Interleukin-16 / physiology. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Membrane Glycoproteins / physiology. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. Thrombospondin 1 / biosynthesis. Thrombospondin 1 / genetics. Thrombospondin 1 / physiology. Transcription, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709867.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-16; 0 / Membrane Glycoproteins; 0 / P-selectin ligand protein; 0 / RNA, Messenger; 0 / Thrombospondin 1; 1HGW4DR56D / Leukotriene B4; EC 3.3.2.- / Epoxide Hydrolases; EC 3.3.2.- / leukotriene A4 hydrolase
  •  go-up   go-down


28. Ueda K, Ito E, Karayama M, Ohsaki E, Nakano K, Watanabe S: KSHV-infected PEL cell lines exhibit a distinct gene expression profile. Biochem Biophys Res Commun; 2010 Apr 9;394(3):482-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV-infected PEL cell lines exhibit a distinct gene expression profile.
  • We analyzed the gene expression profiles of lymphocyte-originated tumor cell lines - primary effusion lymphoma (PEL) cell lines, T-cell leukemia (TCL) cell lines, Burkitt lymphoma (BL) cell lines - and two sets of normal peripheral blood mononuclear cells (PBMCs) - in order to determine characteristic gene expression profiles for each of the former three groups.
  • And we found that these cell lines showed respective typical gene expression profiles and classified into clear four groups, PEL, TCL, BL, and normal PBMCs.
  • Two B lymphocyte-originated tumor cell lines, PEL and BL cell lines, clearly exhibited distinct gene expression profiles, respectively.
  • Even though there was only one line that was co-infected with both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), KSHV seemed to govern the gene expression profile of the co-infected line.
  • These data suggested not only that established typical tumor cell lines show a distinct gene expression profile but also that this profile may be governed by certain viruses.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Lymphoma, Primary Effusion / genetics. Lymphoma, Primary Effusion / virology
  • [MeSH-minor] Angiopoietin-1 / genetics. Cell Line, Tumor. Gene Expression Profiling. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20175997.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-1
  •  go-up   go-down


29. Alarcon F, Bourgain C, Gauthier-Villars M, Planté-Bordeneuve V, Stoppa-Lyonnet D, Bonaïti-Pellié C: PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history. Genet Epidemiol; 2009 Jul;33(5):379-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.
  • Providing valid risk estimates of a genetic disease with variable age of onset is a major challenge for prevention strategies.
  • This article focuses on ascertainment through at least one affected and presents an estimation method based on maximum likelihood, called the Proband's phenotype exclusion likelihood or PEL for estimating age-dependent penetrance using disease status and genotypic information of family members in pedigrees unselected for family history.
  • We studied the properties of the PEL and compared with another method, the prospective likelihood, in terms of bias and efficiency in risk estimate.
  • For that purpose, family samples were simulated under various disease risk models and under various ascertainment patterns.
  • We showed that, whatever the genetic model and the ascertainment scheme, the PEL provided unbiased estimates, whereas the prospective likelihood exhibited some bias in a number of situations.
  • As an illustration, we estimated the disease risk for transthyretin amyloid neuropathy from a French sample and a Portuguese sample and for BRCA1/2 associated breast cancer from a sample ascertained on early-onset breast cancer cases.
  • [MeSH-minor] Age Factors. Amyloid Neuropathies / genetics. Bias (Epidemiology). Breast Neoplasms / genetics. France. Genes, BRCA1. Genes, BRCA2. Humans. Likelihood Functions. Models, Genetic. Models, Statistical. Pedigree. Phenotype. Portugal. Prealbumin / genetics. Risk

  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • HAL archives ouvertes. Full text from .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley-Liss, Inc.
  • [Cites] Genomics. 1999 Dec 15;62(3):369-76 [10644434.001]
  • [Cites] Eur J Hum Genet. 2007 Aug;15(8):831-6 [17473834.001]
  • [Cites] J Med Genet. 2001 Jan;38(1):43-7 [11332399.001]
  • [Cites] J Med Genet. 2002 May;39(5):335-9 [12011152.001]
  • [Cites] Genet Epidemiol. 2003 Apr;24(3):173-80 [12652521.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):e120 [14627687.001]
  • [Cites] Genet Epidemiol. 2004 Sep;27(2):109-17 [15305327.001]
  • [Cites] Hum Hered. 1971;21(6):523-42 [5149961.001]
  • [Cites] Clin Genet. 1977 Oct;12(4):208-12 [334399.001]
  • [Cites] Genet Epidemiol. 1990;7(6):391-407 [2292365.001]
  • [Cites] Am J Hum Genet. 1995 Jan;56(1):265-71 [7825587.001]
  • [Cites] Am J Hum Genet. 1995 Jan;56(1):33-43 [7825595.001]
  • [Cites] Genet Epidemiol. 1995;12(1):13-25 [7713397.001]
  • [Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]
  • [Cites] Am J Hum Genet. 1997 May;60(5):1021-30 [9150149.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Am J Epidemiol. 1998 Oct 1;148(7):623-30 [9778168.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):939-50 [9818066.001]
  • [Cites] Genet Epidemiol. 1999;16(1):15-39 [9915565.001]
  • [Cites] Am J Hum Genet. 1959 Mar;11(1):1-16 [13626932.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):404-13 [15887246.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):1119-31 [10712222.001]
  • (PMID = 19089844.001).
  • [ISSN] 1098-2272
  • [Journal-full-title] Genetic epidemiology
  • [ISO-abbreviation] Genet. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prealbumin
  • [Other-IDs] NLM/ HALMS358140; NLM/ PMC3108000
  •  go-up   go-down


30. Radlińska M, Piekarowicz A, Galimand M, Bujnicki JM: Cloning and preliminary characterization of a GATC-specific beta2-class DNA:m6A methyltransferase encoded by transposon Tn1549 from Enterococcus spp. Pol J Microbiol; 2005;54(3):249-52
REBASE - The Restriction Enzyme Database. gene/protein/disease-specific - REBASE ref# 9191 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cloning and preliminary characterization of a GATC-specific beta2-class DNA:m6A methyltransferase encoded by transposon Tn1549 from Enterococcus spp.
  • A recent study revealed a subfamily of N6-adenine (m6A) methyltransferases that comprises a few functionally studied eukaryotic members acting on mRNA and prokaryotic members acting on DNA as well as numerous uncharacterized open reading frames.
  • Here, we report cloning and functional characterization of a prokaryotic member of this family encoded by transposon Tn1549 from Enterococcus spp.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450842.001).
  • [ISSN] 1733-1331
  • [Journal-full-title] Polish journal of microbiology
  • [ISO-abbreviation] Pol. J. Microbiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA, Bacterial; EC 2.1.1.72 / Site-Specific DNA-Methyltransferase (Adenine-Specific)
  •  go-up   go-down


31. Liao CH, Fett W, Tzean SS, Hoffman G: Detection and sequence analysis of an altered pectate lyase gene in Pseudomonas syringae pv. glycinea and related bacteria. Can J Microbiol; 2006 Nov;52(11):1051-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and sequence analysis of an altered pectate lyase gene in Pseudomonas syringae pv. glycinea and related bacteria.
  • Pectate lyase (PL) is a potent cell wall-degrading enzyme known to play a role in the microbial infection of plants.
  • However, the PL gene (pel) was detected by Southern hybridization in four out of four P. syringae pv. glycinea strains examined.
  • A P. syringae pv. glycinea pel gene was cloned, sequenced, and predicted to encode a protein sharing 70%-90% identity in amino acid sequence with PLs produced by pectolytic pseudomonads and xanthomonads.
  • A series of amino acid and nucleotide sequence analyses reveal that (i) the predicted P. syringae pv. glycinea PL contains two regions in the amino acid sequence that may affect the formation of a beta-helix structure important for the enzyme activity, and (ii) the P. syringae pv. glycinea pel gene contains a single-base insertion, a double-base insertion, and an 18-bp deletion, which can lead to the synthesis of an inactive PL protein.
  • The altered pel sequence was also detected by polymerase chain reaction and nucleotide sequencing in the genomes of other pathovars of P. syringae, including phaseolicola and tagetis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215896.001).
  • [ISSN] 0008-4166
  • [Journal-full-title] Canadian journal of microbiology
  • [ISO-abbreviation] Can. J. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


32. Wong SS, Thomas A, Barbaris B, Lantz RC, Witten ML: Pulmonary evaluation of permissible exposure limit of syntroleum S-8 synthetic jet fuel in mice. Toxicol Sci; 2009 Jun;109(2):312-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary evaluation of permissible exposure limit of syntroleum S-8 synthetic jet fuel in mice.
  • No significant changes in respiratory permeability were exhibited, indicating that there was no loss of epithelial barrier integrity following S-8 exposure.
  • However, morphological examination and morphometric analysis of distal lung tissue, by using transmission electron microscopy, revealed cellular damage in alveolar type II epithelial cells, with significant increases in volume density of lamellar bodies/vacuoles at 352 and 616 S-8 mg/m(3).
  • Moreover, terminal bronchiolar Clara injury, as evidenced by apical membrane blebs, was observed at relatively low concentrations, suggesting if this synthetic jet fuel is utilized, the current permissible exposure limit of 350 mg/m(3) for hydrocarbon fuels should cautiously be applied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Pathol. 2000 Sep-Oct;28(5):656-63 [11026600.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3659-69 [10612293.001]
  • [Cites] Toxicol Ind Health. 2001 Feb;17(1):23-9 [12004922.001]
  • [Cites] Toxicology. 2002 Jun 14;175(1-3):235-45 [12049851.001]
  • [Cites] Toxicol Sci. 2003 Dec;76(2):347-56 [14514957.001]
  • [Cites] Toxicology. 2004 Apr 15;197(2):139-47 [15003324.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):301-8 [15093277.001]
  • [Cites] J Toxicol Environ Health A. 2004 Jul 23;67(14):1109-29 [15205027.001]
  • [Cites] Toxicol Appl Pharmacol. 1984 Aug;75(1):44-51 [6464021.001]
  • [Cites] Scand J Work Environ Health. 1985 Dec;11(6):433-7 [4095521.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):454-64 [3717299.001]
  • [Cites] Hepatology. 1995 May;21(5):1361-72 [7737643.001]
  • [Cites] J Appl Toxicol. 1996 May-Jun;16(3):197-200 [8818858.001]
  • [Cites] Toxicol Ind Health. 1997 Jan-Feb;13(1):43-55 [9098949.001]
  • [Cites] J Occup Environ Med. 1997 Jul;39(7):623-32 [9253723.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):L229-38 [9950884.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jul;21(1):44-53 [10385592.001]
  • [Cites] Toxicol Sci. 1999 Sep;51(1):119-25 [10496683.001]
  • [Cites] J Chromatogr A. 2005 Nov 4;1093(1-2):11-20 [16233866.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):182-5 [16451852.001]
  • [Cites] J Toxicol Sci. 2006 Aug;31(3):219-28 [16960432.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Oct;35(4):479-87 [16690985.001]
  • [Cites] Int J Toxicol. 2007 Jul-Aug;26(4):325-9 [17661223.001]
  • [Cites] Toxicol Sci. 2007 Dec;100(2):415-22 [17890764.001]
  • [Cites] J Appl Toxicol. 2008 May;28(4):543-53 [17966119.001]
  • [Cites] Toxicology. 2008 Dec 5;254(1-2):106-11 [18930109.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):1-8 [8679213.001]
  • [Cites] Toxicol Sci. 2000 Dec;58(2):290-8 [11099641.001]
  • (PMID = 19357071.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES06694
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydrocarbons; 0 / S-8 fuel
  • [Other-IDs] NLM/ PMC2683924
  •  go-up   go-down


33. Lautier T, Blot N, Muskhelishvili G, Nasser W: Integration of two essential virulence modulating signals at the Erwinia chrysanthemi pel gene promoters: a role for Fis in the growth-phase regulation. Mol Microbiol; 2007 Dec;66(6):1491-505
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of two essential virulence modulating signals at the Erwinia chrysanthemi pel gene promoters: a role for Fis in the growth-phase regulation.
  • Production of the essential virulence factors, called pectate lyases (Pels), in the phytopathogenic bacterium Erwinia chrysanthemi is controlled by a complex regulation system and responds to various stimuli, such as the presence of pectin or plant extracts, growth phase, temperature and iron concentration.
  • Eight regulators modulating the expression of the pel genes (encoding Pels) have been characterized.
  • Although many studies have been carried out, the mechanisms of control of Pel production by growth phase have not yet been elucidated.
  • Here we report that a fis mutant of E. chrysanthemi showed a strong increase in transcription of the pel genes during exponential growth whereas induction of expression in the parental strain occurred at the end of exponential growth.
  • This reveals that Fis acts to prevent an efficient transcription of pel genes at the beginning of exponential growth and also provides evidence of the involvement of Fis in the growth-phase regulation of the pel genes.
  • By using in vitro DNA-protein interactions and transcription experiments, we find that Fis directly represses the pel gene expression at the transcription initiation step.
  • In addition, we show that Fis acts in concert with KdgR, the main repressor responding to the presence of pectin compounds, to shut down the pel gene transcription.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028312.001).
  • [ISSN] 0950-382X
  • [Journal-full-title] Molecular microbiology
  • [ISO-abbreviation] Mol. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / KdgR protein, Erwinia chrysanthemi; 0 / Repressor Proteins; 0 / Transcription Factors; 9007-49-2 / DNA; EC 4.2.2.- / PelE protein, Erwinia chrysanthemi; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


34. Metaxa-Mariatou V, Papaioannou D, Loli A, Papadopoulou I, Gazouli M, Mavroudis P, Nasioulas G: Subtype C1 persistent infection of HHV-8 in a PEL patient. Leuk Lymphoma; 2005 Oct;46(10):1507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtype C1 persistent infection of HHV-8 in a PEL patient.
  • PEL, a rare type of lymphoma constituting less than 5% of NHLs, has been recently identified as a distinct clinical and pathological entity among the B-cell lymphomas, with characteristic morphologic, immunophenotypic, molecular and viral features.
  • Using a combination of clinical, morphological, immunohistochemical features and molecular biology techniques in this study we document a PEL case with persistent HHV-8 of genotype C1 infection.
  • [MeSH-minor] Adult. Amino Acid Sequence. Base Sequence. Follow-Up Studies. Genotype. Greece / ethnology. Hodgkin Disease. Humans. Male. Molecular Sequence Data. Phylogeny. Sequence Alignment. Viral Proteins / chemistry. Viral Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194897.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / K1 protein, Human herpesvirus 8; 0 / Viral Proteins
  •  go-up   go-down


35. Santiago-Doménech N, Jiménez-Bemúdez S, Matas AJ, Rose JK, Muñoz-Blanco J, Mercado JA, Quesada MA: Antisense inhibition of a pectate lyase gene supports a role for pectin depolymerization in strawberry fruit softening. J Exp Bot; 2008;59(10):2769-79
Hazardous Substances Data Bank. PECTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense inhibition of a pectate lyase gene supports a role for pectin depolymerization in strawberry fruit softening.
  • It has been reported previously that inhibiting the expression of pectate lyase genes by antisense technology in strawberry (Fragaria x ananassa Duch.) fruit resulted in prolonged fruit firmness.
  • In this present study, three independent transgenic lines were identified exhibiting a greater than 90% reduction in pectate lyase transcript abundance.
  • These results indicate that pectate lyase plays an important degradative role in the primary wall and middle lamella in ripening strawberry fruit, and should be included in synergistic models of cell wall disassembly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Bot. 2001 Aug;52(361):1635-45 [11479328.001]
  • [Cites] Plant Mol Biol. 2001 Sep;47(1-2):311-40 [11554479.001]
  • [Cites] Planta. 2001 Nov;214(1):11-21 [11762160.001]
  • [Cites] Planta. 2001 Dec;214(2):257-64 [11800390.001]
  • [Cites] Plant Physiol. 2002 Feb;128(2):751-9 [11842178.001]
  • [Cites] J Exp Bot. 2002 Oct;53(377):2115-9 [12324535.001]
  • [Cites] Plant Physiol. 2007 Aug;144(4):1693-6 [17687051.001]
  • [Cites] Planta. 2003 Oct;217(6):951-61 [12838420.001]
  • [Cites] Plant Physiol. 1997 Jul;114(3):1071-6 [9232883.001]
  • [Cites] Plant Mol Biol. 1997 Aug;34(6):867-77 [9290639.001]
  • [Cites] Anal Biochem. 1998 Mar 15;257(2):107-11 [9514779.001]
  • [Cites] Plant Physiol Biochem. 2004 Dec;42(10):823-31 [15596102.001]
  • [Cites] Plant Physiol. 2007 Jun;144(2):1012-28 [17449643.001]
  • [Cites] J Exp Bot. 2003 Feb;54(383):633-45 [12554706.001]
  • (PMID = 18522930.001).
  • [ISSN] 1460-2431
  • [Journal-full-title] Journal of experimental botany
  • [ISO-abbreviation] J. Exp. Bot.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pectins; 0 / Plant Proteins; 9000-69-5 / pectin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  • [Other-IDs] NLM/ PMC2486476
  • [Keywords] NOTNLM ; Cell wall / Fragaria / fruit ripening / pectate lyase / pectinases / strawberry
  •  go-up   go-down


36. Cohen R, Steinmaus C, Quinlan P, Ku R, Cooper M, Roberts T: Development of permissible exposure limits: the California experience. Int J Occup Environ Health; 2006 Jul-Sep;12(3):242-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of permissible exposure limits: the California experience.
  • The California OSHA Airborne Contaminant Advisory Committee reviewed several hundred substances and recommended occupational exposure limits with the intent of worker and employer protection.
  • [MeSH-major] Advisory Committees / organization & administration. Hazardous Substances / standards. Occupational Exposure / standards. Occupational Health / legislation & jurisprudence
  • [MeSH-minor] Animals. California. Communication. Humans. Maximum Allowable Concentration. National Institute for Occupational Safety and Health (U.S.) / standards. No-Observed-Adverse-Effect Level. Program Development. United States

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967831.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hazardous Substances
  •  go-up   go-down


37. Palusa SG, Golovkin M, Shin SB, Richardson DN, Reddy AS: Organ-specific, developmental, hormonal and stress regulation of expression of putative pectate lyase genes in Arabidopsis. New Phytol; 2007;174(3):537-50
The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-specific, developmental, hormonal and stress regulation of expression of putative pectate lyase genes in Arabidopsis.
  • Pectate lyases catalyse the eliminative cleavage of de-esterified homogalacturonan in pectin, a major component of the primary cell walls in higher plants.
  • In the completed genome of Arabidopsis, there are 26 genes (AtPLLs) that encode pectate lyase-like proteins.
  • Interestingly, all PLL genes are expressed in flowers.
  • Analysis of expression of all PLL genes in seedlings treated with hormones, abiotic stresses and elicitors of defense responses revealed significant changes in the expression of some PLLs without affecting the other PLLs.
  • The stability of transcripts of PLLs varied considerably among different genes.
  • [MeSH-major] Arabidopsis / genetics. Arabidopsis Proteins / genetics. Gene Expression Regulation, Plant. Polysaccharide-Lyases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447910.001).
  • [ISSN] 0028-646X
  • [Journal-full-title] The New phytologist
  • [ISO-abbreviation] New Phytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Deoxyadenosines; 0 / RNA, Messenger; 73-03-0 / cordycepin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


38. Zhuge B, Du GC, Shen W, Zhuge J, Chen J: Efficient secretory expression of an alkaline pectate lyase gene from Bacillus subtilis in E. coli and the purification and characterization of the protein. Biotechnol Lett; 2007 Mar;29(3):405-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient secretory expression of an alkaline pectate lyase gene from Bacillus subtilis in E. coli and the purification and characterization of the protein.
  • The gene encoding pectate lyase (PL) from Bacillus subtilis WSHB04-02 was amplified by PCR, fused with a periplasmic secretion signal peptide sequence, pelB, from pET22b(+), cloned and expressed in Escherichia coli cells using a temperature control vector, pHsh.
  • [MeSH-minor] Enzyme Activation. Enzyme Stability. Gene Expression Regulation, Bacterial / physiology. Gene Expression Regulation, Enzymologic / physiology. Genetic Enhancement / methods. Recombinant Proteins / biosynthesis. Recombinant Proteins / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237974.001).
  • [ISSN] 1573-6776
  • [Journal-full-title] Biotechnology letters
  • [ISO-abbreviation] Biotechnol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


39. Srinivas U, Kumar R, Pati H, Saxena R, Tyagi S: Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify? Hematology; 2007 Oct;12(5):381-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify?
  • The clinico-hematological profile of 40 cases of acute erythroleukemia (AEL) was evaluated.
  • These were subclassified into three types, namely AML M6a, M6b and M6c based on the myeloblast and proerythroblast percentages.
  • As AEL is biologically an "erythroid predominant" disease, two ratios (PE/MB, PE/TEC) with proerythroblasts as numerator have been formulated.
  • An attempt has been made to assess the difference in these ratios in subclassified AEL.
  • There were 29 M6a, 2M6b,and 9 M6 c patients, which were subclassified using the criteria proposed by Mazzella et al.
  • The incidence of AEL in our study was 3.7%, predominantly affecting males with a predilection to younger age in contrast to Western studies.
  • Both PE/MB and PE/TEC ratios were higher in M6b and M6c in comparison to M6a.
  • The subclassification of AEL becomes essential especially in the era of lineage-targeted therapies, which can lead to the development and use of erythroid specific treatments in the near future.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / classification
  • [MeSH-minor] Adult. Age Factors. Aged. Cell Count. Erythroblasts. Erythroid Cells. Female. Granulocyte Precursor Cells. Humans. Incidence. Male. Middle Aged. Sex Factors

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852448.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Kitagawa J, Hara T, Tsurumi H, Oyama M, Moriwaki H: Pure erythroid leukemia with hemophagocytosis. Intern Med; 2009;48(18):1695-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure erythroid leukemia with hemophagocytosis.
  • Biochemistry showed increased ferritin levels.
  • Pure erythroid leukemia with hemophagocytic syndrome (HPS) was diagnosed.
  • Complete remission was attained, and HPS also improved.
  • However, leukemia relapsed during chemotherapy and the patient died.
  • This is the first report of pure erythroid leukemia complicated with HPS.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / complications. Lymphohistiocytosis, Hemophagocytic / etiology

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755777.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


41. Wong SS, Vargas J, Thomas A, Fastje C, McLaughlin M, Camponovo R, Lantz RC, Heys J, Witten ML: In vivo comparison of epithelial responses for S-8 versus JP-8 jet fuels below permissible exposure limit. Toxicology; 2008 Dec 5;254(1-2):106-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo comparison of epithelial responses for S-8 versus JP-8 jet fuels below permissible exposure limit.
  • This study was designed to characterize and compare the pulmonary effects in distal lung from a low-level exposure to jet propellant-8 fuel (JP-8) and a new synthetic-8 fuel (S-8).
  • A pulmonary function test performed 24h after the final exposure indicated that there was a significant increase in expiratory lung resistance in the S-8 mice, whereas JP-8 mice had significant increases in both inspiratory and expiratory lung resistance compared to control values.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 1999 Dec;20(18):3659-69 [10612293.001]
  • [Cites] Toxicology. 2004 Apr 15;197(2):139-47 [15003324.001]
  • [Cites] Toxicol Sci. 2000 Dec;58(2):290-8 [11099641.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L1075-81 [11943673.001]
  • [Cites] Toxicol Ind Health. 2001 Feb;17(1):23-9 [12004922.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Aug;27(2):170-8 [12151308.001]
  • [Cites] Toxicol Sci. 2003 Dec;76(2):347-56 [14514957.001]
  • [Cites] J Med Dent Sci. 2003 Sep;50(3):195-202 [15074357.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):301-8 [15093277.001]
  • [Cites] J Toxicol Environ Health A. 2004 Jul 23;67(14):1109-29 [15205027.001]
  • [Cites] Acta Psychiatr Scand. 1979 Jul;60(1):39-49 [474176.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1983;303:55-67 [6575584.001]
  • [Cites] Toxicol Appl Pharmacol. 1984 Aug;75(1):44-51 [6464021.001]
  • [Cites] Scand J Work Environ Health. 1985 Dec;11(6):433-7 [4095521.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):454-64 [3717299.001]
  • [Cites] Toxicol Ind Health. 1995 May-Jun;11(3):325-36 [7482572.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):1-8 [8679213.001]
  • [Cites] J Appl Toxicol. 1996 May-Jun;16(3):197-200 [8818858.001]
  • [Cites] Toxicol Ind Health. 1997 Jan-Feb;13(1):43-55 [9098949.001]
  • [Cites] J Occup Environ Med. 1997 Jul;39(7):623-32 [9253723.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):L229-38 [9950884.001]
  • [Cites] Drug Chem Toxicol. 1999 Feb;22(1):155-64 [10189576.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jul;21(1):44-53 [10385592.001]
  • [Cites] Toxicol Sci. 1999 Sep;51(1):119-25 [10496683.001]
  • [Cites] Phys Med Biol. 2005 Apr 7;50(7):1405-19 [15798332.001]
  • [Cites] J Chromatogr A. 2005 Nov 4;1093(1-2):11-20 [16233866.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):182-5 [16451852.001]
  • [Cites] J Toxicol Sci. 2006 Aug;31(3):219-28 [16960432.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Oct;35(4):479-87 [16690985.001]
  • [Cites] Int J Toxicol. 2007 Jul-Aug;26(4):325-9 [17661223.001]
  • [Cites] J Appl Toxicol. 2008 May;28(4):543-53 [17966119.001]
  • [Cites] Toxicol Pathol. 2000 Sep-Oct;28(5):656-63 [11026600.001]
  • (PMID = 18930109.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES006694-14; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694-14
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hydrocarbons; 0 / JP8 aviation fuel; 0 / S-8 fuel
  • [Other-IDs] NLM/ NIHMS208577; NLM/ PMC2927360
  •  go-up   go-down


42. Nair P, Pan H, Stallings RL, Gao SJ: Recurrent genomic imbalances in primary effusion lymphomas. Cancer Genet Cytogenet; 2006 Dec;171(2):119-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphomas (PEL) form a subset of AIDS-related lymphomas and usually have a poor prognosis.
  • Although Kaposi's sarcoma-associated herpes virus (KSHV) is often associated with PEL, very little is known about the exact mechanisms or causative effects of these associations.
  • We investigated the chromosomal imbalances in six KSHV-positive PEL cell lines using comparative genomic hybridization analysis.
  • The recurrent nature of the gains found in these chromosomal regions suggests that these imbalances play roles in the pathogenesis of PEL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Mar 1;101(5):1956-61 [12406869.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):305-19 [16075461.001]
  • [Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Hematol J. 2001;2(3):172-9 [11920242.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):595-601 [12002764.001]
  • [Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] J Med Genet. 1999 Jul;36(7):511-7 [10424810.001]
  • (PMID = 17116491.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NCI NIH HHS / CA / R01 CA096512-02; United States / NCI NIH HHS / CA / R01 CA096512-03; United States / NCI NIH HHS / CA / R01 CA124332; United States / NCI NIH HHS / CA / CA096512-01A2; United States / NCI NIH HHS / CA / CA096512-02; United States / NCI NIH HHS / CA / R01 CA124332-01A2; United States / NCI NIH HHS / CA / R01 CA096512-01A2; United States / NCI NIH HHS / CA / R01 CA096512-04; United States / NCI NIH HHS / CA / R01 CA132637
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS165930; NLM/ PMC2799290
  •  go-up   go-down


43. Towata T, Komizu Y, Suzu S, Ueoka R, Okada S: Highly selective fusion and accumulation of hybrid liposomes into primary effusion lymphoma cells along with induction of apoptosis. Biochem Biophys Res Commun; 2010 Mar 12;393(3):445-8
Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an aggressive neoplasm caused by human herpes virus-8 infection, and is generally resistant to chemotherapy.
  • Hybrid liposomes, composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (21) dodecyl ether (C12(EO)21) (HL-21), were rapidly accumulated in the membrane of PEL cells.
  • HL-21 also increased membrane fluidity of PEL cells, and induced caspase-3 activation along with cell death.
  • These results suggest that HL-21 should be an effective and attractive regent for PEL treatment.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20138834.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0AWH8BFG9A / polidocanol; 30IQX730WE / Polyethylene Glycols; U86ZGC74V5 / Dimyristoylphosphatidylcholine
  •  go-up   go-down


44. Mazzella FM, Smith D, Horn P, Cotelingam JD, Rector JT, Shrit MA, Pesce A, Schumacher HR: Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients. Am J Hematol; 2006 Jul;81(7):484-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast-predominant) and disease (M6b, pronormoblast-predominant).
  • A 20-year retrospective study was performed to identify cases demonstrating >or=50% erythrocytic component and <30% calculated blasts (FAB exclusion criteria) without underlying cause (96 cases).
  • [MeSH-major] Erythroblasts. Leukemia, Erythroblastic, Acute / pathology. Models, Statistical. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Age Factors. Disease-Free Survival. Erythrocyte Count. Erythrocytes / pathology. Granulocyte Precursor Cells / pathology. Humans. Male. Middle Aged. Multivariate Analysis. Platelet Count. Predictive Value of Tests. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755568.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Abraham SK, Schupp N, Schmid U, Stopper H: Antigenotoxic effects of the phytoestrogen pelargonidin chloride and the polyphenol chlorogenic acid. Mol Nutr Food Res; 2007 Jul;51(7):880-7
Hazardous Substances Data Bank. 4-NITROQUINOLINE-N-OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pelargonidin (PEL), a common anthocyanidin with estrogenic activity, was tested in HL-60 cells for its genotoxicity and possible antigenotoxic effects against 4-nitroquinoline 1-oxide (NQO), a potent mutagen and carcinogen which induces oxidative stress.
  • To take into account potential interactions between phytochemicals within normal human nutrition, we evaluated a combination of PEL with the nonestrogenic phytochemical chlorogenic acid (CLA), one of the most abundant polyphenols in the human diet.
  • PEL (< or = 2 microM) and CLA (< or = 800 microM) were nongenotoxic in the micronucleus test.
  • We observed significant antigenotoxic effects against NQO with both compounds, but no additive interaction of PEL and CLA.
  • Flow cytometric analysis of oxidative stress revealed significant protection against NQO-induced oxidative stress by PEL, CLA, and their combination.
  • Furthermore, PEL and CLA prevented the NQO-induced reduction in GSH level.
  • In conclusion, the phytoestrogen PEL revealed antioxidative and antigenotoxic properties in HL-60 cells, but no significant additive interaction with the abundant nutritional polyphenol CLA under the tested conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579891.001).
  • [ISSN] 1613-4125
  • [Journal-full-title] Molecular nutrition & food research
  • [ISO-abbreviation] Mol Nutr Food Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthocyanins; 0 / Antimutagenic Agents; 0 / Mutagens; 0 / Phytoestrogens; 318ADP12RI / Chlorogenic Acid; 56-57-5 / 4-Nitroquinoline-1-oxide; 7690-51-9 / pelargonidin
  •  go-up   go-down


46. Bongini L: Topological properties of the energy landscape of small peptides. Biophys Chem; 2005 Apr 1;115(2-3):145-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The topology of the potential energy landscape (PEL) underlying the dynamics of a two dimensional off-lattice model for a heteropolymer is analyzed for different sequences of amino-acids.
  • A statistical characterization of the metastable minima and first-order saddles of the PEL highlights structural differences in the landscape of good and bad folding sequences and provides insight on the chain dynamics during folding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752597.001).
  • [ISSN] 0301-4622
  • [Journal-full-title] Biophysical chemistry
  • [ISO-abbreviation] Biophys. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Peptides
  •  go-up   go-down


47. Ratel D, Ravanat JL, Berger F, Wion D: N6-methyladenine: the other methylated base of DNA. Bioessays; 2006 Mar;28(3):309-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Contrary to mammalian DNA, which is thought to contain only 5-methylcytosine (m5C), bacterial DNA contains two additional methylated bases, namely N6-methyladenine (m6A), and N4-methylcytosine (m4C).
  • However, if the main function of m5C and m4C in bacteria is protection against restriction enzymes, the roles of m6A are multiple and include, for example, the regulation of virulence and the control of many bacterial DNA functions such as the replication, repair, expression and transposition of DNA.
  • Interestingly, even if adenine methylation is usually considered a bacterial DNA feature, the presence of m6A has been found in protist and plant DNAs.
  • Furthermore, indirect evidence suggests the presence of m6A in mammal DNA, raising the possibility that this base has remained undetected due to the low sensitivity of the analytical methods used.
  • This highlights the importance of considering m6A as the sixth element of DNA.

  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley Periodicals, Inc.
  • [Cites] Mol Cell Biol. 1981 Jul;1(7):600-8 [9279374.001]
  • [Cites] J Androl. 1997 Jul-Aug;18(4):372-7 [9283949.001]
  • [Cites] J Bacteriol. 1997 Sep;179(18):5869-77 [9294447.001]
  • [Cites] Science. 1999 May 7;284(5416):967-70 [10320378.001]
  • [Cites] Nat Biotechnol. 1999 Jun;17(6):517 [10385302.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19538-44 [10391886.001]
  • [Cites] J Bacteriol. 1999 Sep;181(17):5135-9 [10464180.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11578-83 [10500219.001]
  • [Cites] J Bacteriol. 1952 Oct;64(4):557-69 [12999684.001]
  • [Cites] J Bacteriol. 1953 Feb;65(2):113-21 [13034700.001]
  • [Cites] Biochem J. 1958 Apr;68(4):627-36 [13522672.001]
  • [Cites] Biochim Biophys Acta. 1965 Mar 15;95:513-5 [14342545.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52075-81 [15456775.001]
  • [Cites] Curr Opin Microbiol. 2005 Apr;8(2):154-60 [15802246.001]
  • [Cites] Mol Microbiol. 2000 Mar;35(5):1168-79 [10712697.001]
  • [Cites] J Bacteriol. 2000 Jun;182(12):3482-9 [10852881.001]
  • [Cites] Virology. 2000 Jul 5;272(2):409-16 [10873785.001]
  • [Cites] Hum Mol Genet. 2000 Oct;9(16):2395-402 [11005794.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 5;276(3):1261-4 [11027620.001]
  • [Cites] Int Microbiol. 2000 Sep;3(3):139-46 [11032305.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):147-51 [11252956.001]
  • [Cites] J Bacteriol. 2001 May;183(10):3065-75 [11325934.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 20;285(3):800-5 [11453663.001]
  • [Cites] J Am Chem Soc. 2001 Feb 7;123(5):976-7 [11456633.001]
  • [Cites] Biochemistry (Mosc). 2001 Jul;66(7):753-62 [11563955.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7197-204 [11705888.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7610-5 [11705940.001]
  • [Cites] Nucleic Acids Res. 2002 Mar 15;30(6):1364-70 [11884634.001]
  • [Cites] J Cell Sci. 2002 Jun 1;115(Pt 11):2381-8 [12006622.001]
  • [Cites] Mol Microbiol. 2002 Aug;45(3):673-95 [12139615.001]
  • [Cites] EMBO J. 2002 Sep 16;21(18):4969-77 [12234936.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6791-5 [12460886.001]
  • [Cites] FEBS Lett. 2002 Dec 18;532(3):367-72 [12482594.001]
  • [Cites] Plant J. 2003 Nov;36(4):550-64 [14617085.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):476-82 [14733930.001]
  • [Cites] Genes Genet Syst. 2003 Dec;78(6):391-8 [14973340.001]
  • [Cites] Nature. 1970 Mar 7;225(5236):948-9 [4391887.001]
  • [Cites] Biochem J. 1972 Jun;128(1):133-8 [5085550.001]
  • [Cites] J Cell Biol. 1973 Mar;56(3):697-701 [4631666.001]
  • [Cites] Biochim Biophys Acta. 1974 Nov 20;374(1):1-11 [4429738.001]
  • [Cites] Nature. 1975 May 15;255(5505):197-200 [1143315.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Nov;73(11):3923-7 [1069277.001]
  • [Cites] J Bacteriol. 1978 Sep;135(3):1156-7 [99431.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Oct;75(10):4992-6 [105360.001]
  • [Cites] Biochim Biophys Acta. 1979 Jun 20;563(1):72-81 [497215.001]
  • [Cites] Gene. 1983 May-Jun;22(2-3):139-56 [6307815.001]
  • [Cites] J Bacteriol. 1984 Nov;160(2):586-90 [6094478.001]
  • [Cites] Nucleic Acids Res. 1985 Feb 25;13(4):1399-412 [4000939.001]
  • [Cites] J Virol. 1985 Oct;56(1):320-4 [2993662.001]
  • [Cites] J Mol Biol. 1986 May 20;189(2):371-5 [3489102.001]
  • [Cites] Mol Cell Biol. 1986 Jul;6(7):2364-70 [3023930.001]
  • [Cites] J Gen Microbiol. 1986 Nov;132(11):3055-9 [3114425.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Sep 30;147(3):1082-7 [3663209.001]
  • [Cites] Trends Genet. 1989 May;5(5):139-43 [2667217.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2598-605 [2548083.001]
  • [Cites] Mol Cell Biol. 1989 Nov;9(11):4759-66 [2689864.001]
  • [Cites] Cell. 1990 Sep 7;62(5):981-9 [2203541.001]
  • [Cites] Biochem Cell Biol. 1990 Jun;68(6):944-8 [2168719.001]
  • [Cites] Eur J Biochem. 1990 Dec 12;194(2):513-20 [1702711.001]
  • [Cites] Exp Parasitol. 1991 May;72(4):339-44 [1851101.001]
  • [Cites] Nucleic Acids Res. 1992 Apr 11;20(7):1483-6 [1579439.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5351-6 [1437552.001]
  • [Cites] J Mol Biol. 1994 Jan 14;235(2):472-85 [8289276.001]
  • [Cites] Cell. 1994 Feb 11;76(3):577-88 [7906204.001]
  • [Cites] Gene. 1994 Dec 30;151(1-2):89-95 [7828910.001]
  • [Cites] Plant J. 1995 Feb;7(2):221-33 [7704046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1210-4 [8577742.001]
  • [Cites] Transgenic Res. 1995 Sep;4(5):324-31 [8589735.001]
  • [Cites] Gene. 1997 May 6;190(2):237-44 [9197539.001]
  • [Cites] J Bacteriol. 1997 Jul;179(13):4254-63 [9209041.001]
  • [Cites] Trends Genet. 1997 Aug;13(8):335-40 [9260521.001]
  • (PMID = 16479578.001).
  • [ISSN] 0265-9247
  • [Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology
  • [ISO-abbreviation] Bioessays
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA; JAC85A2161 / Adenine; W7IBY2BGAX / 6-methyladenine
  • [Number-of-references] 91
  • [Other-IDs] NLM/ HALMS390682; NLM/ PMC2754416
  •  go-up   go-down


48. O'Hara AJ, Vahrson W, Dittmer DP: Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood; 2008 Feb 15;111(4):2347-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma.
  • MicroRNAs are regulated by gene alteration, transcription, and processing.
  • Thus far, few studies have simultaneously assessed all 3 levels of regulation.
  • Using real-time quantitative polymerase chain reaction (QPCR)-based arrays, we determined changes in gene copy number, pre-miRNA, and mature miRNA levels for the largest set of primary effusion lymphomas (PELs) to date.
  • We detected PEL-specific miRNA gene amplifications, and concordant changes in pre-miRNA and mature miRNA.
  • We identified 68 PEL-specific miRNAs.
  • This defines the miRNA signature of PEL and shows that transcriptional regulation of pre-miRNA as well as mature miRNA levels contribute nonredundant information that can be used for the classification of human tumors.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1454-61 [12424116.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1511-8 [15070997.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):185-97 [15260970.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):343-9 [15372041.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] Nucleic Acids Res. 2005;33(8):2697-706 [15891114.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5394-403 [16192569.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):e182 [16314296.001]
  • [Cites] J Virol. 2006 Jun;80(11):5321-6 [16699012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3068-71 [16849646.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Dec;171(2):119-21 [17116491.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Nature. 2000 Mar 16;404(6775):293-6 [10749213.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] J Infect Dis. 2007 Mar 1;195(5):645-59 [17262705.001]
  • [Cites] Oncogene. 2007 May 31;26(26):3769-76 [17173072.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]
  • [Cites] Nat Biotechnol. 2007 Sep;25(9):996-7 [17846629.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • (PMID = 18079361.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121947; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIDCR NIH HHS / DE / DE018304-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2234063
  •  go-up   go-down


49. Hussain AR, Ahmed M, Ahmed SO, Al-Thari S, Khan AS, Razack S, Platanias LC, Al-Kuraya KS, Uddin S: Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells. Leuk Lymphoma; 2009 Jul;50(7):1204-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an incurable, aggressive B-cell malignancy that develops rapid resistance to conventional chemotherapy.
  • MG-132, a proteasome inhibitor, suppresses cell proliferation and induces apoptosis in several PEL cell lines.
  • Treatment of PEL cells with MG-132 results in downregulation of S-phase kinase protein 2 (SKP2) and accumulation of p27Kip1.
  • Furthermore, MG-132 treatment of PEL cells causes Bax conformational changes, leading to loss of mitochondrial membrane potential and release of cytochrome c to the cytosole.
  • Such cytochrome c release results in sequential activation of caspases and apoptosis, while pretreatment of PEL cells with universal inhibitor of caspases, z-VAD-fmk prevents cell death induced by MG-132.
  • Finally, our data demonstrated in PEL cells that MG-132 downregulates the expression of inhibitor of apoptosis proteins XIAP, cIAP1 and survivin.
  • Altogether, these findings suggest that MG-132 is a potent inducer of apoptosis of PEL cells via downregulation of SKP2 leading to accumulation of p27Kip1, resulting in cell cycle arrest and apoptosis and strongly suggest that targeting the proteasomal pathway may provide a novel therapeutic approach for the treatment of PEL.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Gene Expression Regulation, Neoplastic. Leupeptins / pharmacology. Lymphoma, Primary Effusion / drug therapy. Lymphoma, Primary Effusion / pathology. S-Phase Kinase-Associated Proteins / metabolism

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19557642.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Leupeptins; 0 / Microtubule-Associated Proteins; 0 / S-Phase Kinase-Associated Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 9007-43-6 / Cytochromes c
  •  go-up   go-down


50. Bubman D, Guasparri I, Cesarman E: Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene; 2007 Jul 26;26(34):4979-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection by Kaposi's sarcoma herpesvirus (KSHV)/human herpesvirus-8.
  • However, no structural abnormalities were found in the c-myc oncogene in PEL.
  • Given that c-Myc is often involved in lymphomagenesis, we hypothesized that it is deregulated in PEL.
  • We report that PEL cells have abnormally stable c-Myc protein.
  • Our data show that the impaired c-Myc degradation in PEL cells is associated with a significant underphosphorylation of c-Myc T58.
  • Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3beta-mediated c-Myc T58 phosphorylation is restored.
  • The presence of c-Myc and LANA in GSK-3beta-containing complexes in PEL cells further confirms the significance of these interactions in naturally KSHV-infected cells.
  • [MeSH-minor] B-Lymphocytes / metabolism. B-Lymphocytes / virology. Cell Line. Glycogen Synthase Kinase 3 / metabolism. Humans. RNA Interference. Threonine / metabolism


51. Haddad L, El Hajj H, Abou-Merhi R, Kfoury Y, Mahieux R, El-Sabban M, Bazarbachi A: KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells. Leukemia; 2008 Apr;22(4):826-34
Genetic Alliance. consumer health - Primary effusion lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of primary effusion lymphoma (PEL) and of Kaposi's sarcoma.
  • PEL is an aggressive proliferation of B cells with poor prognosis.
  • We evaluated both in vitro and in vivo the potential role of angiogenic factors secreted by PEL cells, that is, their interaction with endothelial cells and their implication in the invasive behavior of tumoral cells.
  • In vitro, PEL-induced angiogenesis is dependent on vascular endothelial growth factor (VEGF) and VEGF receptors.
  • However, although PEL cells produce VEGF and basic fibroblast growth factor (b-FGF) transcripts, they only secrete VEGF in vitro.
  • In vivo, very high levels of both VEGF and b-FGF were found in the ascitic fluid of NOD/SCID mice injected with PEL cells.
  • We then show evidence of cell adhesion and gap junction-mediated heterocellular communication between PEL cells and endothelial cells.
  • Finally, we show that PEL cells extravasate through the endothelial barrier and that the specific tyrosine kinase inhibitor of VEGF receptors, PTK-787/ZK-222584, the anti-VEGF antibody, bevacizumab or the gap junction inhibitor 18-alpha-glycyrrhetinic acid, partially attenuate PEL cell extravasation.
  • Angiogenesis, cell adhesion and communication likely contribute to the development of PEL and represent potential therapeutic targets.
  • [MeSH-minor] Animals. Cell Transformation, Viral. Coculture Techniques. Disease Models, Animal. Endothelial Cells / pathology. Gap Junctions / pathology. Humans. Mice. Neoplasms, Experimental. Paracrine Communication. Transplantation, Heterologous. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094712.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


52. Carbone A, Cesarman E, Gloghini A, Drexler HG: Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS; 2010 Feb 20;24(4):479-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a very rare subgroup of B-cell lymphomas presenting as pleural, peritoneal and pericardial neoplastic effusions in the absence of a solid tumor mass or recognizable nodal involvement.
  • There is strong evidence that Kaposi's sarcoma-associated herpesvirus (KSHV) is a causal agent of PEL.
  • PEL tumor cells are latently infected by KSHV with consistent expression of several viral proteins and microRNAs that can affect cellular proliferation, differentiation and survival.
  • The most relevant data on pathogenesis and biology of KSHV have been provided by studies on PEL-derived cell lines.
  • Fourteen continuous cell lines have been established from the malignant effusions of patients with AIDS-associated and non-AIDS-associated PEL.
  • The PEL cell lines display unique features and are clearly distinct from other lymphoma cell lines.
  • PEL cell lines represent an indispensable tool for the understanding of KSHV biology and its impact on the clinical manifestation of PEL.
  • Studies on PEL cell lines have shown that a number of viral genes, expressed during latency or lytic life cycle, have effects on cell binding, proliferation, angiogenesis and inflammation.
  • Also, PEL cell lines are important model systems for the study of the disorder of PEL including the lack of invasive or destructive growth patterns and the peculiar propensity of PEL to involve body cavity surfaces.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Trends Genet. 1998 Apr;14(4):144-50 [9594662.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Adv Cancer Res. 1998;75:57-86 [9709807.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Adv Cancer Res. 1999;76:121-60 [10218100.001]
  • [Cites] Trends Microbiol. 1999 May;7(5):196-200 [10354594.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] Adv Virus Res. 1999;52:139-232 [10384236.001]
  • [Cites] J Med Virol. 1999 Aug;58(4):394-401 [10421407.001]
  • [Cites] J Infect Dis. 1999 Sep;180(3):824-8 [10438372.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4984-9 [10519412.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):415-9 [15621832.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Leuk Res. 2005 May;29(5):545-55 [15755507.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] Int J Hematol. 2002 Aug;76(2):165-72 [12215016.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):833-40 [12802923.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):913-6 [12808126.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):170-5 [2371971.001]
  • [Cites] Blood. 1993 Jul 1;82(1):247-61 [8100721.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2794-804 [9184224.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Radiology. 1997 Nov;205(2):459-63 [9356629.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2430-40 [16508017.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):335-47 [16604559.001]
  • [Cites] J Pathol. 2006 Aug;209(4):464-73 [16741895.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:185-209 [17089798.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Acta Haematol. 2007;117(3):132-44 [17135726.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1285-92 [17368758.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] PLoS Pathog. 2007 Sep 7;3(9):1348-60 [17907806.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Blood. 2008 Jan 1;111(1):320-7 [17890449.001]
  • [Cites] J Cell Sci. 2008 Feb 15;121(Pt 4):450-7 [18211958.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2077-83 [10925292.001]
  • (PMID = 20051807.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA068939; United States / NCI NIH HHS / CA / R01 CA103646; United States / NCI NIH HHS / CA / R01CA068939; United States / NCI NIH HHS / CA / R01CA103646
  • [Publication-type] Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS492494; NLM/ PMC3740588
  •  go-up   go-down


53. Kishimoto K, Kitamura T, Hirayama Y, Tate G, Mitsuya T: Cytologic and immunocytochemical features of EBV negative primary effusion lymphoma: report on seven Japanese cases. Diagn Cytopathol; 2009 Apr;37(4):293-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is very rare type of non-Hodgkin's lymphoma (NHL) usually confined to the body cavities such as the pleural space, pericardium, and peritoneum.
  • PEL is a human herpes virus-8 (HHV-8)-associated lymphoma and commonly observed in human immunodeficiency virus (HIV)-infected patients.
  • However, HIV-infected patients are extremely fewer in Japan in comparison with those in Western countries; PEL is usually not associated with HIV infection in Japan.
  • This report presents seven Japanese cases of PEL.
  • In situ hybridization revealed that the PEL cells were negative for EBV in all cases.
  • An immunocytological analysis showed that only one case was positive for HHV-8, and PEL cells were positive for CD20 in all cases.
  • However, the cytomorphological features of PEL cells showed large cell size, abundant basophilic cytoplasm, coarse chromatin, and occasional binucleated or multinucleated cells, similar to a large cell immunoblastic and anaplastic large cell lymphoma, indicating that the cytomorphological characteristics of PE cells in Giemsa and Papanicolaou stain were consistent with those reported abroad.
  • The prognosis for PEL in these cases was poor, but the survival time was variable ranging from 1 month to 54 months, and was different from that of Western cases.
  • No p16/CDKN2A expression was observed, and one case showed PEL cells with a BLIMP1 mutation.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217041.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Gasperini P, Tosato G: Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia; 2009 Oct;23(10):1867-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a fatal malignancy, which typically presents as a lymphomatous effusion that later disseminates.
  • Rapamycin (Rapa), which targets mTOR (mammalian target of Rapa), is currently evaluated as a treatment for PEL, but the recent development of PEL in Rapa-treated post-transplant recipients questions the drug's use in PEL.
  • Here, we used a murine model of PEL effusion that mimics the human disease to investigate the anti-PEL activity of Rapa.
  • Initially, Rapa reduced PEL load compared with control mice, but most mice rapidly showed PEL progression.
  • Levels of VEGF, which promotes vascular permeability contributing to effusion formation, were significantly reduced in ascites of Rapa-treated mice compared with controls.
  • Expression of IL-10, the principal autocrine growth factor for PEL, was initially reduced in PEL from Rapa-treated mice but rapidly increased despite treatment.
  • We found that the hypoxic environment of ascites and Rapa cooperate in stimulating IL-10 expression in PEL, which likely contributes to the emergence of drug resistance.
  • These results identify Rapa an effective drug to reduce PEL effusions but illustrate the rapid development of drug resistance, which likely limits the efficacy of Rapa in PEL.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] Am J Transplant. 2008 Mar;8(3):707-10 [18261181.001]
  • [Cites] Eur J Immunol. 2001 Feb;31(2):350-9 [11180098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2604-9 [11226286.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3042-9 [11698289.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Feb;3(2):295-304 [12020063.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4472-80 [12907620.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] J Lab Clin Med. 1971 Dec;78(6):1006 [5131833.001]
  • [Cites] South Med J. 1981 May;74(5):585-9 [6787716.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):376-85 [7529135.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2652-60 [9635593.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):904-8 [15640348.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] J Physiol. 2006 Jul 1;574(Pt 1):275-81 [16675496.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):159-70 [16904613.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Transplantation. 2007 Apr 27;83(8):1114-21 [17452903.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Mol Cell. 1999 Dec;4(6):915-24 [10635317.001]
  • (PMID = 19554030.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / NIH0012215497; United States / PHS HHS / / NIH0012215497; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factors; 130068-27-8 / Interleukin-10; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS113595; NLM/ PMC2940422
  •  go-up   go-down


55. Zenda T, Tominaga K, Choto S, Okada T, Kaneko S, Minato H: [Diffuse large B-cell lymphoma initially manifested by massive ascites and a small gastric lesion, clinically mimicking primary effusion lymphoma (PEL) in the abdominal cavity: a case report and review of the literature on Japanese PEL patients]. Nihon Shokakibyo Gakkai Zasshi; 2007 Dec;104(12):1772-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse large B-cell lymphoma initially manifested by massive ascites and a small gastric lesion, clinically mimicking primary effusion lymphoma (PEL) in the abdominal cavity: a case report and review of the literature on Japanese PEL patients].
  • The patient was treated with chemotherapy including rituximab (R-CHOP-ESHAP) and injection of methotrexate and dexamethasone into the medullary cavity as well as radiation to the whole brain, and achieved complete remission 4 months later.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Primary Effusion / diagnosis
  • [MeSH-minor] Ascites / complications. Diagnosis, Differential. Humans. Male. Middle Aged. Stomach Neoplasms / pathology


56. Bidwell LA, Bowker RM: Evaluation of changes in architecture of the stratum internum of the hoof wall from fetal, newborn, and yearling horses. Am J Vet Res; 2006 Dec;67(12):1947-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate morphologic changes of the stratum internum of hooves from near-term fetal, newborn, and yearling horses.
  • PROCEDURES: Primary epidermal laminae (PEL) of the stratum internum were examined for evidence of architectural changes.
  • RESULTS: In near-term fetuses, the PEL had a homogeneous appearance and symmetric distribution around the hoof wall with no significant differences in PEL density between the toe and quarters.
  • However after birth, branched laminae at the toe formed within the first few weeks, which significantly increased PEL density at the toe, compared with the quarters.
  • In yearlings, morphology of the PEL differed from that in younger foals and the PEL density was significantly greater at the toe than the quarters.
  • The PEL density at the toe and medial and lateral quarters was significantly different from each other, as these PEL densities appeared to have been associated with conformation.
  • No significant differences in PEL densities between forefeet and hind feet were detected in any group.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Findings indicate that the stratum internum of the inner hoof wall undergoes several morphologic changes shortly after birth.
  • The PEL become branched with a greater PEL density at the toe than the quarters.
  • In an asymmetric foot, more PEL were associated with the sloping side than the steep side of the foot.
  • Findings suggested that PEL growth may also occur by bifurcation as well as by mitosis from the coronet and that wall stress may be associated with increased PEL density.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144792.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Niino D, Tsukasaki K, Torii K, Imanishi D, Tsuchiya T, Onimaru Y, Tsushima H, Yoshida S, Yamada Y, Kamihira S, Tomonaga M: Human herpes virus 8-negative primary effusion lymphoma with BCL6 rearrangement in a patient with idiopathic CD4 positive T-lymphocytopenia. Haematologica; 2008 Jan;93(1):e21-3
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) was initially designated as a body-cavity-based lymphoma and recognized as a distinct clinical entity without a contiguous tumor mass.
  • PEL was first reported in patients with acquired immunodeficiency syndrome (AIDS) and the distinctive feature of PEL originally reported as a B-cell neoplasm characterized by infection of the tumor cells by human herpes virus 8 (HHV-8).
  • However, there have recently been several reports of PEL in patients without human immunodeficiency virus (HIV) or HHV-8 infection.
  • [MeSH-major] Antigens, CD4 / biosynthesis. DNA-Binding Proteins / genetics. Gene Rearrangement. Herpesvirus 8, Human / genetics. Lymphoma, Primary Effusion / genetics. Lymphopenia / therapy. T-Lymphocytes / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / pharmacology. Dyspnea / diagnosis. HIV Infections / diagnosis. Humans. Immunophenotyping. Male. Pericardial Effusion

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - T-Lymphocytopenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166773.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  •  go-up   go-down


58. Muñoz-Fontela C, Marcos-Villar L, Hernandez F, Gallego P, Rodriguez E, Arroyo J, Gao SJ, Avila J, Rivas C: Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Virol; 2008 Feb;82(3):1518-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the causal agent of both KS and primary effusion lymphoma (PEL).
  • Although treatment with paclitaxel has significant antitumor activity in KS, drug resistance represents a major obstacle for improving the overall response and survival of PEL patients.
  • This paper focuses on the mechanism of paclitaxel resistance observed in PEL cells.
  • This is the first demonstration of paclitaxel resistance induced by a viral protein and suggests a link between the expression of LANA2 and the resistance of PEL cells to paclitaxel.

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1979 Feb 22;277(5698):665-7 [423966.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1858-62 [1057175.001]
  • [Cites] J Biol Chem. 1981 Oct 25;256(20):10435-41 [6116707.001]
  • [Cites] J Cell Biol. 1981 Nov;91(2 Pt 1):479-87 [6118377.001]
  • [Cites] J Cell Biol. 1982 Sep;94(3):688-96 [6127342.001]
  • [Cites] J Cell Biol. 1984 Mar;98(3):1017-25 [6199362.001]
  • [Cites] J Cell Biol. 1984 Sep;99(3):940-6 [6147357.001]
  • [Cites] Ann N Y Acad Sci. 1986;466:745-56 [2873781.001]
  • [Cites] J Cell Biol. 1987 Feb;104(2):277-88 [3543024.001]
  • [Cites] J Cell Biol. 1987 Feb;104(2):289-302 [2879846.001]
  • [Cites] Methods Enzymol. 1986;134:89-104 [3821583.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2597-606 [3315650.001]
  • [Cites] J Cell Biol. 1987 Nov;105(5):2167-77 [3316248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9040-4 [3321065.001]
  • [Cites] Mol Med. 1995 Jul;1(5):506-26 [8529117.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):816-25 [8631019.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):623-31 [9231689.001]
  • [Cites] Chem Biol. 1995 Sep;2(9):569-73 [9383460.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;39(1):73-90 [9453715.001]
  • [Cites] Curr Opin Cell Biol. 1998 Feb;10(1):123-30 [9484604.001]
  • [Cites] Curr Opin Oncol. 1998 Sep;10(5):413-21 [9800111.001]
  • [Cites] Methods Cell Biol. 1999;61:267-95 [9891320.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):1061-70 [10071301.001]
  • [Cites] Int J Cancer. 1999 Oct 8;83(2):151-6 [10471519.001]
  • [Cites] Exp Cell Res. 2005 Nov 15;311(1):96-105 [16214130.001]
  • [Cites] J Cell Biol. 1988 Apr;106(4):1213-20 [3283150.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4093-100 [2898289.001]
  • [Cites] FASEB J. 1989 Mar;3(5):1593-9 [2646163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(24):9553-7 [2263610.001]
  • [Cites] J Biol Chem. 1991 Feb 25;266(6):3987-94 [1671676.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2212-22 [2009540.001]
  • [Cites] Trends Pharmacol Sci. 1992 Apr;13(4):134-6 [1350385.001]
  • [Cites] Biochemistry. 1995 Feb 21;34(7):2203-11 [7857932.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2619-28 [10861441.001]
  • [Cites] J Virol. 2000 Sep;74(17):8194-201 [10933732.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11737-42 [11562465.001]
  • [Cites] Annu Rev Med. 2002;53:615-27 [11818492.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):621-8 [12168109.001]
  • [Cites] Am J Clin Dermatol. 2002;3(7):451-62 [12180893.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3260-8 [12761496.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1463-70 [12771415.001]
  • [Cites] Biochem J. 2003 Sep 1;374(Pt 2):545-50 [12767255.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49795-805 [14527951.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7643-54 [14668346.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1699-704 [15343345.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5 [6103535.001]
  • (PMID = 18032494.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Viral Proteins; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2224414
  •  go-up   go-down


59. Mack AA, Sugden B: EBV is necessary for proliferation of dually infected primary effusion lymphoma cells. Cancer Res; 2008 Sep 1;68(17):6963-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are found together in approximately 80% of primary effusion lymphomas (PEL), but their contribution to these cancers is unclear.
  • We found that dominant-negative derivatives of EBNA1 inhibited EBV-positive PEL cells from forming colonies.
  • Those rare PEL cells that proliferated after expression of the dominant-negative derivatives usually expressed these derivatives at low or undetectable levels and continued to maintain their EBV genomes.
  • Those proliferating cells expressing higher levels of the derivatives expressed mutant derivatives that could not bind DNA.
  • These findings indicate that EBV is required to sustain proliferation, as measured by colony formation of dually infected PEL cells.
  • Surprisingly, they did inhibit the colony-forming ability of EBV-negative, KSHV-positive PEL cells.
  • These findings indicate that the site-specific DNA-binding activity of EBNA1 or its derivatives when expressed efficiently in EBV-negative, KSHV-positive PEL cells inhibits their colony formation possibly through their binding to the KSHV genome.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2833-42 [18037963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] J Virol. 1990 May;64(5):2407-10 [2157896.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):170-5 [2371971.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Mod Pathol. 1995 Jan;8(1):39-45 [7731940.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Plasmid. 2007 Jul;58(1):1-12 [17350094.001]
  • [Cites] EMBO J. 2007 Oct 3;26(19):4252-62 [17853891.001]
  • [Cites] Blood. 2008 Jan 1;111(1):320-7 [17890449.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):1-22 [11960692.001]
  • (PMID = 18757410.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009135-26; United States / NCI NIH HHS / CA / CA022443-26; United States / NCI NIH HHS / CA / P01 CA022443-280004; United States / NCI NIH HHS / CA / P01 CA022443-260004; United States / NCI NIH HHS / CA / T32 CA009135-25; United States / NCI NIH HHS / CA / T32 CA09135; United States / NCI NIH HHS / CA / P01 CA022443-26; United States / NCI NIH HHS / CA / CA009135-27; United States / NCI NIH HHS / CA / P01 CA022443-270004; United States / NCI NIH HHS / CA / CA022443-270004; United States / NCI NIH HHS / CA / T32 CA009135-24; United States / NCI NIH HHS / CA / CA022443-300004; United States / NCI NIH HHS / CA / P01 CA022443-29; United States / NCI NIH HHS / CA / P01 CA022443-210004; United States / NCI NIH HHS / CA / CA022443-27; United States / NCI NIH HHS / CA / P01 CA022443-23S1; United States / NCI NIH HHS / CA / P01 CA022443-267738; United States / NCI NIH HHS / CA / CA022443-260004; United States / NCI NIH HHS / CA / P01 CA022443-220004; United States / NCI NIH HHS / CA / P01 CA022443-22; United States / NCI NIH HHS / CA / P01 CA022443-200004; United States / NCI NIH HHS / CA / P01 CA022443-300004; United States / NCI NIH HHS / CA / P01 CA022443-24; United States / NCI NIH HHS / CA / CA022443-23S1; United States / NCI NIH HHS / CA / CA009135-29; United States / NCI NIH HHS / CA / CA009135-25; United States / NCI NIH HHS / CA / P01 CA022443-290004; United States / NCI NIH HHS / CA / CA009135-26; United States / NCI NIH HHS / CA / P01 CA022443-24S10004; United States / NCI NIH HHS / CA / P01 CA022443-25; United States / NCI NIH HHS / CA / CA022443-23; United States / NCI NIH HHS / CA / CA022443-290004; United States / NCI NIH HHS / CA / CA022443-24S10004; United States / NCI NIH HHS / CA / P01 CA022443-30; United States / NCI NIH HHS / CA / T32 CA009135-28; United States / NCI NIH HHS / CA / P01 CA022443-240004; United States / NCI NIH HHS / CA / CA022443-240004; United States / NCI NIH HHS / CA / CA022443-25; United States / NCI NIH HHS / CA / T32 CA009135-31A2; United States / NCI NIH HHS / CA / P01 CA022443-250004; United States / NCI NIH HHS / CA / CA022443-23S10004; United States / NCI NIH HHS / CA / CA022443-250004; United States / NCI NIH HHS / CA / CA022443-230004; United States / NCI NIH HHS / CA / CA022443-220004; United States / NCI NIH HHS / CA / P01 CA022443-27; United States / NCI NIH HHS / CA / CA009135-24; United States / NCI NIH HHS / CA / P01 CA022443-230004; United States / NCI NIH HHS / CA / P01 CA022443-28; United States / NCI NIH HHS / CA / CA022443-24; United States / NCI NIH HHS / CA / T32 CA009135-29; United States / NCI NIH HHS / CA / CA022443-210004; United States / NCI NIH HHS / CA / CA022443-22; United States / NCI NIH HHS / CA / CA022443-29; United States / NCI NIH HHS / CA / CA022443-267738; United States / NCI NIH HHS / CA / P01 CA022443-23S10004; United States / NCI NIH HHS / CA / CA022443-280004; United States / NCI NIH HHS / CA / CA009135-30; United States / NCI NIH HHS / CA / CA009135-28; United States / NCI NIH HHS / CA / T32 CA009135-27; United States / NCI NIH HHS / CA / CA022443-24S1; United States / NCI NIH HHS / CA / CA022443-28; United States / NCI NIH HHS / CA / P01 CA022443-24S1; United States / NCI NIH HHS / CA / CA022443-200004; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / T32 CA009135; United States / NCI NIH HHS / CA / T32 CA009135-30; United States / NCI NIH HHS / CA / CA009135-31A2; United States / NCI NIH HHS / CA / P01 CA022443-23; United States / NCI NIH HHS / CA / CA22443
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens
  • [Other-IDs] NLM/ NIHMS58012; NLM/ PMC2587434
  •  go-up   go-down


60. Tanaka PY, Atala MM, Pereira J, Caterino-de-Araujo A: Primary effusion lymphoma with cardiac involvement in HIV positive patient-complete response and long survival with chemotherapy and HAART. J Clin Virol; 2009 Jan;44(1):84-5
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare type of lymphoma related to herpesvirus-8 (HHV-8), and considered an AIDS-defining condition.
  • The authors describe a case of PEL with cardiac involvement occurring in an HIV-positive patient treated with HAART and chemotherapy, who achieved complete remission and long survival.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. HIV Long-Term Survivors. Heart Neoplasms / secondary. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis


61. Gloux K, Touze T, Pagot Y, Jouan B, Blanco C: Mutations of ousA alter the virulence of Erwinia chrysanthemi. Mol Plant Microbe Interact; 2005 Feb;18(2):150-7
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The disruption of the ousA gene encoding the major osmoprotectant uptake system highly enhanced bacterial virulence on potato tubers.
  • In the absence of oxygen, pectate lyase (Pel) production was significantly higher in the tissue macerated with the ousA- strain than with the wild type.
  • In minimal medium, ousA disruption enhanced Pel production and pelE expression only under micro-aerobiosis conditions.
  • The effect on Pel was reversed by reintroduction of the ousA gene.
  • The osmoprotectectants glycine betaine, proline betaine, and pipecolic acid are known to be taken up via OusA and to have an inhibitory effect on Pel production.
  • However, their effects on Pel activity were not (glycine betaine) or only weakly (proline and pipecolic acid) affected by ousA disruption.
  • Furthermore, no correlation was observed between their effects on Pel activities and their osmoprotection efficacies.
  • The evidence indicates that ousA and osmoprotectant effects on Pel are not linked to osmoregulation and that complex regulations exist between Pel production, ousA, and osmoprotection via compounds liberated during the plant infection.
  • [MeSH-minor] Gene Expression Regulation, Bacterial / physiology. Osmosis. Oxygen. Plant Tubers / microbiology. Polysaccharide-Lyases / biosynthesis. Polysaccharide-Lyases / metabolism. Solanum tuberosum / microbiology. Virulence / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720084.001).
  • [ISSN] 0894-0282
  • [Journal-full-title] Molecular plant-microbe interactions : MPMI
  • [ISO-abbreviation] Mol. Plant Microbe Interact.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Membrane Transport Proteins; 0 / OusA protein, Erwinia chrysanthemi; EC 4.2.2.- / PelE protein, Erwinia chrysanthemi; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase; S88TT14065 / Oxygen
  •  go-up   go-down


62. Towata T, Komizu Y, Suzu S, Matsumoto Y, Ueoka R, Okada S: Hybrid liposomes inhibit the growth of primary effusion lymphoma in vitro and in vivo. Leuk Res; 2010 Jul;34(7):906-11
Genetic Alliance. consumer health - Primary effusion lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an aggressive neoplasm caused by Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection.
  • Hybrid liposomes (HL), composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene dodecyl ether, inhibited PEL cell proliferation and induced apoptosis in vitro.
  • Intraperitoneal inoculation of the BCBL-1 PEL cell line into NOD/Scid/Jak3 deficient mice induced massive ascites, which were inhibited by HL21 without significant systemic toxicity in the mice.
  • These results suggest that HL21 is an effective and attractive reagent for PEL treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20074798.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 0 / polyoxyethylene-10-dodecyl ether; 30IQX730WE / Polyethylene Glycols; EC 2.7.10.2 / Jak3 protein, mouse; EC 2.7.10.2 / Janus Kinase 3; U86ZGC74V5 / Dimyristoylphosphatidylcholine
  •  go-up   go-down


63. Snozek CL, Saenger AK, Greipp PR, Bryant SC, Kyle RA, Rajkumar SV, Katzmann JA: Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma. Clin Chem; 2007 Jun;53(6):1099-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two common albumin assays, bromcresol green (BCG) and agarose gel protein electrophoresis (PEL), frequently yield discordant results, creating confusion regarding which assay is superior for use in myeloma.
  • METHODS: We measured albumin by BCG on a Roche Modular system, by PEL with a Helena SPIFE SPE Vis agarose gel, and by immunonephelometry performed on a Dade Behring BNII nephelometer.
  • BCG and PEL were used to measure albumin in 5777 patient samples, and all 3 methods were used in an additional 252 samples.
  • RESULTS: For sera with zero/low monoclonal immunoglobulin protein (M)-spike (0 to <15 g/L), results for both BCG and PEL correlated well to nephelometry, although median PEL results were 8 g/L lower than corresponding BCG measurements.
  • Correlation between PEL and nephelometry or BCG diminished with increasing M-spike, with PEL eventually overestimating albumin compared with both other assays.
  • For 35% of myeloma patients, discrepancy between BCG and PEL had a potentially clinically significant effect on staging, but no difference in group survival was found.
  • CONCLUSIONS: Both BCG and PEL correlate well to nephelometry in sera with zero/low M-spikes.
  • In the presence of larger M-spikes, PEL correlates poorly to nephelometry or BCG, whereas BCG compares well with nephelometry regardless of M-spike.
  • [MeSH-major] Bromcresol Green. Multiple Myeloma / diagnosis. Serum Albumin / analysis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17463172.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62242
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indicators and Reagents; 0 / Paraproteins; 0 / Serum Albumin; 8YGN0Y942M / Bromcresol Green
  •  go-up   go-down


64. Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R: Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells. Cancer Res; 2007 Jul 15;67(14):7003-10
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV).
  • PEL is poorly responsive to standard cytotoxic chemotherapy and portends a poor survival.
  • It is known that KSHV encodes two lytic genes, ORF36 (phosphotransferase) and KSHV ORF21 (thymidine kinase), which can phosphorylate ganciclovir and azidothymidine, respectively.
  • Here, we have explored whether these genes can be used as therapeutic targets for PEL.
  • PEL arises in pleural spaces and other effusions that provide a hypoxic environment.
  • Based on Northern blot analysis, exposure of PEL cells to hypoxia up-regulated the expression of both ORF36 and ORF21.
  • Using a newly developed nonradioactive reverse-phase high-performance liquid chromatography/mass spectrometry method to separate and quantify the phosphorylated forms of ganciclovir and azidothymidine, we found that PEL cells exposed to hypoxia produced increased amounts of the toxic triphosphates of these drugs.
  • Moreover, we found that hypoxia increased the cell toxicity of ganciclovir and azidothymidine in PEL cells but had no significant effect on the herpesvirus-negative cell line CA46.
  • These findings may have clinical applicability in the development of effective therapies for PEL or other KSHV-related malignancies.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638913.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


65. Cai SL, Lin JH, Wang CM, Lin L: [Improvement of the the thermostability of Penicillium expansum lipase by mutagenesis the random mutant ep8 at K55R]. Sheng Wu Gong Cheng Xue Bao; 2007 Jul;23(4):677-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to improve the thermostability of the Penicillium expansum Lipase (PEL), the lipase encoding genes was mutated by site-directed mutagenesis.
  • A recombinant vector pAO815-ep8-K55R which contain double mutant genes was constructed by overlap extension PCR using the cDNA of a random-mutant lipase ep8 (a single site mutant) as the template and two special primers were used to generate another mutation site K55R.
  • The recombinant vector was transformed into Pichia pastoris GS115 by electroporation and the recombinant mutant GS-pAO815-ep8- K55R can secret double-mutant lipase PEL-ep8-K55R-GS into the medium when it was induced by Methanol.
  • The yield of the double-mutant lipase is 508 u/mL, which is 81% that of the wild type lipase PEL-GS (627 u/mL) and 55% that of random-mutant PEL-ep8-GS (924 u/mL).
  • The specific activity of double-mutant lipase is 2309.1 u/mg, which is similar to random-mutant lipase PEL-ep8-GS and the wild type lipase PEL-GS.
  • The optimum temperature of the double-mutant lipase is same with the wild type lipase PEL-GS and random-mutant lipase PEL-ep8-GS.
  • While the Tm of the double-mutant lipase is 41.0 degrees C, 2.3 degrees C higher than the wild type lipase PEL-GS and 0.8% higher than the random-mutant lipase PEL-ep8-GS, indicating that the double-mutant lipase PEL-ep8-K55R-GS has higher thermostability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822043.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / Recombinant Proteins; EC 3.1.1.3 / Lipase
  •  go-up   go-down


66. Petre CE, Sin SH, Dittmer DP: Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol; 2007 Feb;81(4):1912-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is associated with Kaposi's sarcoma (KS) as well as primary effusion lymphomas (PEL).
  • However, DNA-damaging drugs such as doxorubicin are clinically efficacious against PEL and KS, suggesting that p53 signaling remains intact despite the presence of KSHV.
  • To investigate the functionality of p53 in PEL, we examined the response of a large number of PEL cell lines to doxorubicin.
  • Two out of seven (29%) PEL cell lines harbored a mutant p53 allele (BCBL-1 and BCP-1) which led to doxorubicin resistance.
  • In contrast, all other PEL containing wild-type p53 showed DNA damage-induced cell cycle arrest, p53 phosphorylation, and p53 target gene activation.
  • Supporting this finding, chemical inhibition of p53 signaling in PEL led to doxorubicin resistance, and chemical activation of p53 by the Hdm2 antagonist Nutlin-3 led to unimpaired induction of p53 target genes as well as growth inhibition and apoptosis.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Science. 1999 Sep 10;285(5434):1733-7 [10481009.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):431-44 [15558026.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]
  • [Cites] J Virol. 1997 Feb;71(2):1629-34 [8995690.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] Oncogene. 2000 Mar 30;19(14):1834-42 [10777217.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] Oncogene. 1998 Mar;16(11):1429-41 [9525742.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1674-7 [9733514.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1677-9 [9733515.001]
  • [Cites] J Virol. 2005 Jul;79(13):8637-50 [15956606.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3169-76 [16540668.001]
  • [Cites] Blood. 2006 May 15;107(10):4122-9 [16439677.001]
  • [Cites] Blood. 2006 May 15;107(10):4109-14 [16439685.001]
  • [Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]
  • [Cites] J Virol. 2006 Sep;80(18):9017-30 [16940514.001]
  • [Cites] Arch Ophthalmol. 2006 Sep;124(9):1269-75 [16966622.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):33036-44 [16905769.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Infect Dis. 2001 Jul 15;184(2):119-26 [11424007.001]
  • [Cites] Nature. 2001 Aug 30;412(6850):865-6 [11528457.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):383-93 [11839653.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7 [14595027.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):993-1000 [14707282.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] J Virol. 2004 Sep;78(18):10074-85 [15331740.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Cancer Lett. 1993 May 14;69(3):151-60 [8513440.001]
  • (PMID = 17121789.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / T32 CA009156; United States / NCI NIH HHS / CA / CA009156; United States / NCI NIH HHS / CA / CA700580; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NCI NIH HHS / CA / CA109232-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Imidazoles; 0 / Piperazines; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 80168379AG / Doxorubicin; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC1797584
  •  go-up   go-down


67. Sirianni MC, Libi F, Campagna M, Rossi D, Capello D, Sciaranghella G, Carbone A, Simonelli C, Monini P, Gaidano G, Ensoli B: Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. Br J Haematol; 2005 Jul;130(1):92-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development.
  • Primary effusion lymphomas (PELs) are invariably infected by human herpesvirus type 8 (HHV8) and often co-infected by Epstein-Barr virus (EBV).
  • We found that expression of major histocompatibility complex class I (MHC-I) surface molecules was significantly decreased in PEL cells when compared with HHV8 negative lymphomas, irrespective of EBV infection.
  • MHC-I downregulation rendered PEL cells sensitive to recognition and killing by natural killer (NK) cells.
  • Intriguingly, analysis of MHC-I non-restricted cytotoxicity in two PEL patients indicated a reduced NK cell activity when compared with healthy individuals.
  • These data suggest that PEL outgrowth may require an impaired NK cell function.
  • [MeSH-major] B-Lymphocytes / immunology. Herpesviridae Infections / immunology. Herpesvirus 8, Human. Histocompatibility Antigens Class I / analysis. Killer Cells, Natural / immunology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / virology
  • [MeSH-minor] Biomarkers / analysis. Case-Control Studies. Cytotoxicity Tests, Immunologic. DNA, Viral / analysis. Down-Regulation. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / genetics. Humans. Serologic Tests

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Oct;131(2):282
  • (PMID = 16044583.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


68. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Previously, we showed that KSHV latency associated nuclear antigen (LANA) stabilizes intracellular activated Notch1 (ICN) involved in maintenance of the malignant phenotype of KSHV infected PEL cells in vitro.
  • The gamma-secretase inhibitor (GSI) which specifically blocks the production of ICN slows down the proliferation of the KSHV infected PEL cell lines BCBL1, BC3 as well as JSC1 in vitro.
  • In this study, we extended these studies to explore the possibility that manipulation of the Notch signaling by GSI would prevent the growth of the PEL tumors in vivo.
  • We observed that the onset of tumorigenesis of KSHV infected PELs was significantly delayed in GSI treated SCID mice harboring the PEL cell lines.
  • We also found that GSI treatment resulted in necrosis as well as apoptosis in tumors generated by the xenotransplanted KSHV positive PEL cell lines.
  • In contrast, GSI had no effect on mice harboring BJAB cells, a KSHV negative Burkitt's lymphoma cell line where ICN levels were negligible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


69. Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T: Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull; 2010 Jul 30;82(5-6):279-83
Hazardous Substances Data Bank. APOMORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parkinson's disease (PD) is a neuropathological and debilitating disorder involving the degeneration of mesencephalic dopaminergic neurons.
  • Neuroprotective effect of pelargonidin (Pel) has already been reported, therefore, this study examined whether Pel administration would attenuate behavioural and structural abnormalities and markers of oxidative stress in an experimental model of PD in rat.
  • For this purpose, unilateral intrastriatal 6-hydroxydopamine (6-OHDA, 12.5mug/5mul of saline-ascorbate)-lesioned rats were pre-treated p.o. with Pel (10 and/or 20mg/kg).
  • Pel administration dose-dependently attenuated the rotational behavior in lesioned rats and protected the neurons of SNC against 6-OHDA toxicity.
  • In addition, pre-treatment with Pel (20mg/kg) significantly decreased the 6-OHDA-induced thiobarbituric acid reactive substances (TBARS) formation, indicative of a neuroprotection against lipid peroxidation.
  • Furthermore, the increase of nitrite levels induced by 6-OHDA, indicate the nitric oxide formation and free radicals production and the decrease of antioxidant defense enzyme superoxide dismutase (SOD) was non-significantly prevented by Pel (20mg/kg).
  • In summary, Pel administration has a dose-dependent neuroprotective effect against 6-OHDA toxicity, partly through attenuating oxidative stress.
  • [MeSH-minor] Administration, Oral. Animals. Antiparkinson Agents / pharmacology. Apomorphine / pharmacology. Cell Count / methods. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Interactions. Lipid Peroxidation / drug effects. Male. Mesencephalon / drug effects. Mesencephalon / metabolism. Neurons / drug effects. Neurons / metabolism. Nitric Oxide / metabolism. Rats. Rats, Wistar. Statistics, Nonparametric. Superoxide Dismutase / metabolism. Thiobarbituric Acid Reactive Substances / metabolism

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20558255.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthocyanins; 0 / Antiparkinson Agents; 0 / Neuroprotective Agents; 0 / Thiobarbituric Acid Reactive Substances; 31C4KY9ESH / Nitric Oxide; 7690-51-9 / pelargonidin; 8HW4YBZ748 / Oxidopamine; EC 1.15.1.1 / Superoxide Dismutase; N21FAR7B4S / Apomorphine
  •  go-up   go-down


70. Coupland SE, Charlotte F, Mansour G, Maloum K, Hummel M, Stein H: HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man. Am J Surg Pathol; 2005 May;29(5):647-52
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man.
  • Primary effusion lymphoma (PEL) is an uncommon large cell lymphoma, usually seen in human immunodeficiency virus (HIV)-infected patients.
  • PEL is characterized by various clinical, histomorphologic, and immunophenotypical features, and is associated with the human herpes virus 8 (HHV-8).
  • PEL may present as either a body cavity-based lymphomatous effusion or a solid tumor mass.
  • Most so-called "solid PEL" usually have an extranodal location; exceptionally rarely, they occur in lymph nodes.
  • The majority of PEL consist of malignant cells of B-cell genotype; seldom they are of T-cell origin.
  • We report a rare case of HHV-8-associated "solid PEL" of T-cell type in a 41-year-old HIV-seropositive man with a concomitant peritoneal effusion.
  • The T-cell lymphoma was diagnosed on the basis of morphologic, immunophenotypic, and molecular findings of a lymph node biopsy.
  • The tumor cells strongly expressed CD45R0, CD7, CD43, MUM1/IRF4, CD30, HHV-8, and EBER, and demonstrated a clonal rearrangement of T-cell receptor-gamma chain gene.
  • The following case provides another example of a lymph node-based "solid" PEL, demonstrating the variety within the spectrum of HHV-8-associated lymphoma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Clone Cells. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Male

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832089.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


71. Wu W, Rochford R, Toomey L, Harrington W Jr, Feuer G: Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk Res; 2005 May;29(5):545-55
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus/human herpesvirus type-8 (KSHV/HHV-8) is associated with primary effusion lymphomas (PEL), a rare form of B-cell lymphoma.
  • PEL cell lines infected with HHV-8, but negative for Epstein-Barr virus (EBV), were analyzed for their tumorigenic potential in a small animal model system.
  • Inoculation of PEL cell lines into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice results in efficient engraftment and tumorigenesis in vivo.
  • PEL-engrafted NOD/SCID (PEL/SCID) mice displayed malignant ascites development with notable abdominal distension, consistent with the clinical manifestations of PEL in humans.
  • Azidothymidine (AZT, zidovudine) and interferon-alpha (IFN-alpha) induce apoptosis in HHV-8+/EBV- PEL cells in culture, by induction of a tumor necrosis factor-related apoptosis inducing ligand (TRAIL) mediated suicide program and has been proposed as a therapy for herpesvirus-associated lymphomas.
  • Daily injection of AZT and IFN-alpha significantly increased mean survival time (MST) of PEL/SCID mice suggesting that induction of apoptosis in PEL cells in vivo may be exploited as an effective relatively non-toxic therapy targeting HHV-8 infected PEL.
  • These data demonstrate that the PEL/SCID mouse is an important preclinical model to characterize efficacy and anti-tumor mechanisms of new therapeutic targets in vivo and will be useful in the design and testing of agents in viral lymphoproliferative diseases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755507.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Interferon-alpha; 0 / Membrane Glycoproteins; 0 / Reverse Transcriptase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor-alpha; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


72. Zhang H, Yang XY, Hong T, Feldman T, Bhattacharyya PK: Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: Report of a case in an HIV-positive patient with simultaneous kaposi sarcoma and a review of the literature. Acta Haematol; 2010;123(4):237-41
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: Report of a case in an HIV-positive patient with simultaneous kaposi sarcoma and a review of the literature.
  • BACKGROUND: Kaposi sarcoma-associated herpesvirus (KSHV), or human herpesvirus type 8 (HHV8), is consistently identified in 2 human immunodeficiency virus (HIV)-associated lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease.
  • These solid variants of PEL are similar morphologically, immunophenotypically, clinically and genetically to classic PEL.
  • CASE REPORT: Here we report a case of a 46-year-old HIV-positive patient with lymphadenopathy and Kaposi sarcoma of the skin.
  • The lymph node biopsy shows a KSHV/HHV8-positive high-grade B-cell lymphoma with co-infection with Epstein-Barr virus, which supports the diagnosis of a solid variant of PEL.
  • CONCLUSION: Analysis of viral infection is of primary importance to define this solid variant of PEL.
  • It is believed that it is related to a few latent viral gene products including ORF73, ORF72, and ORF71 which increase proliferation and impair apoptosis through variant regulatory processes.
  • To the best of our knowledge, this is the first reported case of solid tissue PEL along with Kaposi sarcoma involving the same anatomic site.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 S. Karger AG, Basel.
  • (PMID = 20484888.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Number-of-references] 22
  •  go-up   go-down


73. Sarek G, Ojala PM: p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle; 2007 Sep 15;6(18):2205-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV infection is the causative agent in three different tumor types: Kaposi's sarcoma, a plasmablastic variant of multicentric Castelman's disease and an AIDS-related form of B cell lymphoproliferative disorder called primary effusion lymphoma (PEL).
  • PEL manifests as an effusion malignancy in Kaposi's sarcoma patients with advanced AIDS, but also occurs in HIV-negative individuals.
  • PEL is a very aggressive disease, and currently there are no efficient therapies for treating PEL.
  • In our recent paper we report that p53 reactivation by a small molecule inhibitor of p53-MDM2 interaction, Nutlin-3a, induces selective and massive apoptosis in PEL cells, and has striking anti-tumor activity in a mouse xenograft PEL model.
  • In the light of current treatment regimens for PEL, we discuss here the benefits of using reactivation of the p53 pathway as a novel principle for the treatment of this virally induced highly aggressive malignancy.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890905.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 66
  •  go-up   go-down


74. Ouattara HG, Reverchon S, Niamke SL, Nasser W: Biochemical properties of pectate lyases produced by three different Bacillus strains isolated from fermenting cocoa beans and characterization of their cloned genes. Appl Environ Microbiol; 2010 Aug;76(15):5214-20
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical properties of pectate lyases produced by three different Bacillus strains isolated from fermenting cocoa beans and characterization of their cloned genes.
  • In this study, we characterized three extracellular pectate lyases (Pels) produced by bacilli isolated from fermenting cocoa beans.
  • These enzymes, named Pel-22, Pel-66, and Pel-90, were synthesized by Bacillus pumilus BS22, Bacillus subtilis BS66, and Bacillus fusiformis BS90, respectively.
  • Pel-22 had a low specific activity compared with the other two enzymes.
  • However, it displayed high affinity for the substrate, about 2.5-fold higher than those of Pel-66 and Pel-90.
  • The optimum pHs were 7.5 for Pel-22 and 8.0 for Pel-66 and Pel-90.
  • A synergistic effect was observed between Pel-22 and Pel-66 and between Pel-22 and Pel-90, but not between Pel-90 and Pel-66.
  • The Pels were also strongly active on highly methylated pectins (up to 60% for Pel-66 and Pel-90 and up to 75% for Pel-22).
  • Fe(2+) was found to be a better cofactor than Ca(2+) for Pel-22 activity, while Ca(2+) was the best cofactor for Pel-66 and Pel-90.
  • The amino acid sequences deduced from the cloned genes showed the characteristics of Pels belonging to Family 1.
  • The pel-66 and pel-90 genes appear to be very similar, but they are different from the pel-22 gene.
  • The characterized enzymes form two groups, Pel-66/Pel-90 and Pel-22; members of the different groups might cooperate to depolymerize pectin during the fermentation of cocoa beans.

  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1992 Mar;174(6):2039-42 [1548242.001]
  • [Cites] Biochimie. 1990 Sep;72(9):689-95 [2126210.001]
  • [Cites] Mol Plant Microbe Interact. 1995 Mar-Apr;8(2):207-17 [7756691.001]
  • [Cites] Nat Struct Biol. 1994 Oct;1(10):717-23 [7634076.001]
  • [Cites] Annu Rev Microbiol. 1996;50:213-57 [8905080.001]
  • [Cites] J Bacteriol. 1996 Dec;178(24):7187-96 [8955401.001]
  • [Cites] J Bacteriol. 1997 Apr;179(8):2503-11 [9098045.001]
  • [Cites] J Bacteriol. 1997 Dec;179(23):7321-30 [9393696.001]
  • [Cites] Appl Environ Microbiol. 1998 Apr;64(4):1477-83 [9546184.001]
  • [Cites] J Bacteriol. 1999 Mar;181(5):1652-63 [10049400.001]
  • [Cites] Biochim Biophys Acta. 1999 Apr 19;1427(2):145-54 [10216231.001]
  • [Cites] J Bacteriol. 1999 Jun;181(12):3705-9 [10368144.001]
  • [Cites] Biosci Biotechnol Biochem. 1999 Jun;63(6):998-1005 [10427684.001]
  • [Cites] J Biotechnol. 2006 Feb 10;121(3):390-401 [16168510.001]
  • [Cites] Microbiology. 2006 Mar;152(Pt 3):617-25 [16514142.001]
  • [Cites] Mol Plant Microbe Interact. 2006 Mar;19(3):280-7 [16570658.001]
  • [Cites] Biotechnol Lett. 2007 Mar;29(3):405-10 [17237974.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D233-8 [18838391.001]
  • [Cites] Biosci Biotechnol Biochem. 2009 Feb;73(2):268-73 [19202269.001]
  • [Cites] Microbiology. 2000 Jan;146 ( Pt 1):89-95 [10658655.001]
  • [Cites] Biochem J. 2001 Apr 1;355(Pt 1):155-65 [11256960.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9139-45 [14670977.001]
  • [Cites] Appl Microbiol Biotechnol. 2004 May;64(4):560-7 [14673544.001]
  • [Cites] Crit Rev Food Sci Nutr. 2004;44(4):205-21 [15462126.001]
  • [Cites] Arch Biochem Biophys. 1968 Feb;123(2):298-306 [5642600.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Bacteriol. 1984 Sep;159(3):825-31 [6090392.001]
  • [Cites] FEBS Lett. 1993 Dec 13;335(3):319-26 [8262178.001]
  • (PMID = 20543060.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GU576909/ GU576910/ GU576911
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations, Divalent; 0 / Coenzymes; 0 / DNA, Bacterial; 0 / Pectins; 0 / Recombinant Proteins; 9046-38-2 / polygalacturonic acid; E1UOL152H7 / Iron; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2916476
  •  go-up   go-down


75. Mylona E, Baraboutis IG, Georgiou O, Rondogianni D, Lekakis LJ, Papastamopoulos V, Apostolidis I, Skoutelis AT: Solid variant of primary effusion lymphoma in successfully treated HIV infection: a case report. Int J STD AIDS; 2008 Aug;19(8):570-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a unique form of non-Hodgkin lymphoma, mainly met in severely immunocompromised, HIV-positive patients.
  • PEL is aetiologically related to human herpes virus-8 (HHV-8) and it usually presents as a lymphomatous body cavity effusion in the absence of a solid tumour mass.
  • Recently, cases of HIV-positive patients with HHV-8-positive solid tissue lymphomas, not associated with an effusion, have been reported (solid variant of PEL).
  • The prognosis of PEL is reported to be poor.
  • We report a case of an HIV-positive patient with a typical solid variant of PEL without effusion.
  • Interestingly, his disease developed while being on stable antiretroviral therapy (ART) with high CD4 counts.


76. Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM: Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest; 2007 Apr;117(4):1019-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma herpesvirus (KSHV) is the etiologic agent for primary effusion lymphoma (PEL), a non-Hodgkin type lymphoma manifesting as an effusion malignancy in the affected individual.
  • Although KSHV has been recognized as a tumor virus for over a decade, the pathways for its tumorigenic conversion are incompletely understood, which has greatly hampered the development of efficient therapies for KSHV-induced malignancies like PEL and Kaposi's sarcoma.
  • There are no current therapies effective against the aggressive, KSHV-induced PEL.
  • Here we demonstrate that activation of the p53 pathway using murine double minute 2 (MDM2) inhibitor Nutlin-3a conveyed specific and highly potent activation of PEL cell killing.
  • Our results demonstrated that the KSHV latency-associated nuclear antigen (LANA) bound to both p53 and MDM2 and that the MDM2 inhibitor Nutlin-3a disrupted the p53-MDM2-LANA complex and selectively induced massive apoptosis in PEL cells.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, p53. Herpesvirus 8, Human / physiology. Lymphoma / virology. Sarcoma, Kaposi / genetics. Tumor Suppressor Protein p53 / genetics


77. Lubyova B, Kellum MJ, Frisancho JA, Pitha PM: Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. J Biol Chem; 2007 Nov 2;282(44):31944-53
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma-associated herpesvirus is associated with two lymphoproliferative disorders, primary effusion lymphoma (PEL) and Castleman disease.
  • In PEL, Kaposi sarcoma-associated herpesvirus is present in a latent form expressing only few viral genes.
  • To study the role of vIRF-3 in PEL lymphomagenesis, we analyzed the interaction of vIRF-3 with cellular proteins.
  • The vIRF-3 and MM-1alpha interaction was also demonstrated by glutathione S-transferase pulldown assay and coimmunoprecipitation of endogenous vIRF-3 and MM-1alpha in PEL-derived cell lines.
  • Overexpression of vIRF-3 enhanced the c-Myc-dependent transcription of the gene cdk4.
  • Furthermore, the recruitment of vIRF-3 to the cdk4 promoter and the elevated levels of the histone H3 acetylation suggest the direct involvement of vIRF-3 in the activation of c-Myc-mediated transcription.
  • These findings indicate that vIRF-3 can effectively stimulate c-Myc function in PEL cells and consequently contribute to de-regulation of B-cell growth and differentiation.
  • [MeSH-minor] Cell Line, Tumor. Gene Library. Humans. Two-Hybrid System Techniques

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728244.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA76946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factor-3; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-myc; 0 / Viral Proteins; 0 / viral interferon regulatory factors
  •  go-up   go-down


78. Dyson OF, Bryan BA, Lambert PJ, Ford PW, Akula SM: Beta1 integrins mediate tubule formation induced by supernatants derived from KSHV-infected cells. Intervirology; 2007;50(4):245-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a recently concluded study, we identified Kaposi's sarcoma-associated herpesvirus (KSHV)-infected cells derived from primary effusion lymphoma (PEL) to overexpress vascular endothelial growth factor (VEGF) that had the propensity to mediate tubule formation on a Matrigel, an indicator of angiogenesis.
  • The objective of this study was to determine the receptor molecules that mediate the tubule formation induced by the supernatant derived from KSHV-infected PEL cells.
  • METHODS: The identity of receptor(s) that play a role in mediating tubule formation driven by PEL supernatant was determined by the classical in vitro angiogenesis assay conducted on a Matrigel.
  • RESULTS: RGD peptides, antibodies, and siRNA specific to beta1 integrins significantly lowered the ability of the PEL supernatants to induce tubule formation by endothelial cells. beta1 Integrins mediated tubule formation to comparable levels in endothelial cells that were incubated with supernatants derived from uninduced or TPA-induced PEL cells.
  • CONCLUSION: We report for the first time a critical role for beta1 integrins in angiogenesis supported by the supernatant from KSHV-infected PEL cells.
  • [MeSH-minor] B-Lymphocytes / virology. Cell Line, Transformed. Cell Transformation, Viral. Cells, Cultured. Collagen. Drug Combinations. Endothelium, Vascular / cytology. Herpesviridae Infections / virology. Humans. Laminin. Proteoglycans. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17460413.001).
  • [ISSN] 1423-0100
  • [Journal-full-title] Intervirology
  • [ISO-abbreviation] Intervirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Culture Media, Conditioned; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 0 / Vascular Endothelial Growth Factor A; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


79. Shim HW, Lee JH, Hwang TS, Rhee YW, Bae YM, Choi JS, Han J, Lee CS: Patterning of proteins and cells on functionalized surfaces prepared by polyelectrolyte multilayers and micromolding in capillaries. Biosens Bioelectron; 2007 Jun 15;22(12):3188-95
Hazardous Substances Data Bank. POLYDIMETHYLSILOXANES .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second region was the polyelectrolyte (PEL) coated surface that promoted protein and cell immobilization.
  • The difference in surface functionality between the PEL region and background PEG microstructures resulted in simple patterning of biomolecules.
  • Fluorescein isothiocyanate-tagged bovine serum albumin, E. coli expressing green fluorescence protein (GFP), and fibroblast cells were successfully bound to the exposed PEL surfaces at micron scale.
  • Compared with the simple adsorption of protein, fluorescence intensity was dramatically improved (by about six-fold) on the PEL-modified surfaces.
  • Although animal cell patterning is prerequisite for adhesive protein layer to survive on desired area, the PEL surface without adhesive proteins provides affordable microenvironment for cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400439.001).
  • [ISSN] 0956-5663
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dimethylpolysiloxanes; 0 / Electrolytes; 0 / Proteins; 0 / Silicones; 30IQX730WE / Polyethylene Glycols; 63148-62-9 / baysilon
  •  go-up   go-down


80. Ratel D, Ravanat JL, Charles MP, Platet N, Breuillaud L, Lunardi J, Berger F, Wion D: Undetectable levels of N6-methyl adenine in mouse DNA: Cloning and analysis of PRED28, a gene coding for a putative mammalian DNA adenine methyltransferase. FEBS Lett; 2006 May 29;580(13):3179-84
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undetectable levels of N6-methyl adenine in mouse DNA: Cloning and analysis of PRED28, a gene coding for a putative mammalian DNA adenine methyltransferase.
  • Three methylated bases, 5-methylcytosine, N4-methylcytosine and N6-methyladenine (m6A), can be found in DNA.
  • To reinvestigate the presence of m6A in mammalian DNA, we used a highly sensitive method capable of detecting one N6-methyldeoxyadenosine per million nucleosides.
  • Our results suggest that the total mouse genome contains, if any, less than 10(3) m6A.

  • HAL archives ouvertes. Full text from .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16684535.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 5142-22-3 / 1-methyladenine; EC 2.1.1.72 / PRED28 protein, mouse; EC 2.1.1.72 / Site-Specific DNA-Methyltransferase (Adenine-Specific); JAC85A2161 / Adenine
  •  go-up   go-down


81. Fernández ME, Alfonso J, Brocco MA, Frasch AC: Conserved cellular function and stress-mediated regulation among members of the proteolipid protein family. J Neurosci Res; 2010 May 1;88(6):1298-308
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously identified M6a as a stress responsive gene and shown that M6a is involved in filopodium/spine outgrowth and, likely, synapse formation.
  • M6a belongs to the proteolipid protein (PLP) family, all of their members having four transmembrane domains that allow their localization at the plasma membrane.
  • In the present work, we analyzed other members of this family, the closely related M6b as well as PLP and its splice variant DM20.
  • We found that chronic restraint stress in mice reduces M6b and DM20, but not PLP, mRNA levels in the hippocampus.
  • In addition, M6b and DM20, but again not PLP, induce filopodium formation in primary cultures of hippocampal neurons.
  • Several M6b protein isoforms were studied, all of them having similar effects except for the one lacking the transmembrane domains.
  • [MeSH-minor] Animals. COS Cells. Cell Line, Tumor. Cells, Cultured. Cercopithecus aethiops. Chronic Disease. Disease Models, Animal. Male. Membrane Glycoproteins / metabolism. Mice. Mice, Inbred C57BL. Myelin Proteolipid Protein / metabolism. Nerve Tissue Proteins / metabolism. Protein Isoforms / metabolism. RNA, Messenger / metabolism. Restraint, Physical

  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19937804.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpm6a protein, mouse; 0 / Membrane Glycoproteins; 0 / Myelin Proteolipid Protein; 0 / Nerve Tissue Proteins; 0 / Plp1 protein, mouse; 0 / Protein Isoforms; 0 / Proteolipids; 0 / RNA, Messenger
  •  go-up   go-down


82. Heuer A: Exploring the potential energy landscape of glass-forming systems: from inherent structures via metabasins to macroscopic transport. J Phys Condens Matter; 2008 Sep 17;20(37):373101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review a systematic analysis of the potential energy landscape (PEL) of glass-forming systems is presented.
  • The relevant energy scales of the PEL can be characterized.
  • The relation to the geometric properties of the PEL is stressed.
  • The emergence of length scales within the PEL approach as well as the nature of finite-size effects is discussed.
  • Furthermore, the PEL view is compared to other approaches describing the glass transition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21694408.001).
  • [ISSN] 0953-8984
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Wong EL, Damania B: Linking KSHV to human cancer. Curr Oncol Rep; 2005 Sep;7(5):349-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV is the etiologic agent associated with the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
  • Here, we review the association of KSHV with human cancer, viral genes that may potentially be involved in the neoplastic process, and current therapies used to treat KS, PEL, and MCD.
  • [MeSH-minor] Animals. Biopsy. Cell Transformation, Neoplastic. Cytokines / metabolism. Genes, Viral. Genome, Viral. Giant Lymph Node Hyperplasia / therapy. Giant Lymph Node Hyperplasia / virology. Humans. Lymphoma / therapy. Lymphoma / virology. Sarcoma, Kaposi / therapy. Sarcoma, Kaposi / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091195.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 5T32AI007001; United States / NCI NIH HHS / CA / CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 80
  •  go-up   go-down


84. Wen KW, Damania B: Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett; 2010 Mar 28;289(2):140-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV has been associated with the development of three neoplastic diseases: Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD).
  • In this review, we discuss the three KSHV-associated malignancies, KSHV genome, latent and lytic aspects of the viral lifecycle, putative viral oncogenes, as well as therapeutic regimens used for the treatment of KS, PEL, and MCD.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19651473.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA019014; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIAID NIH HHS / AI / T32 AI007001; United States / NIGMS NIH HHS / GM / T32-GM008719; United States / NIGMS NIH HHS / GM / T32 GM008719; United States / NIAID NIH HHS / AI / T32-AI007001; United States / NHLBI NIH HHS / HL / R01 HL083469; United States / NIDCR NIH HHS / DE / R01 DE018281; United States / NCI NIH HHS / CA / R01 CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Ireland
  • [Number-of-references] 158
  • [Other-IDs] NLM/ NIHMS663850; NLM/ PMC4342847
  •  go-up   go-down


85. Takahashi-Makise N, Suzu S, Hiyoshi M, Ohsugi T, Katano H, Umezawa K, Okada S: Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer; 2009 Sep 15;125(6):1464-72
National BioResource Project. culture/stock collections - NBRP resources .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a unique and recently identified non-Hodgkin's lymphoma that was originally identified in patients with AIDS.
  • PEL is caused by the Kaposi sarcoma-associated herpes virus (KSHV/HHV-8) and shows a peculiar presentation involving liquid growth in the serous body cavity and a poor prognosis.
  • As the nuclear factor (NF)-kappaB pathway is activated in PEL and plays a central role in oncogenesis, we examined the effect of a biscoclaurine alkaloid, cepharanthine (CEP) on PEL derived cell lines (BCBL-1, TY-1 and RM-P1), in vitro and in vivo.
  • An methylthiotetrazole assay revealed that the cell proliferation of PEL cell lines was significantly suppressed by the addition of CEP (1-10 microg/ml).
  • CEP also inhibited NF-kappaB activation and induced apoptotic cell death in PEL cell lines.
  • We established a PEL animal model by intraperitoneal injection of BCBL-1, which led to the development of ascites and diffuse infiltration of organs, without obvious solid lymphoma formation, which resembles the diffuse nature of human PEL.
  • These results indicate that NF-kappaB could be an ideal molecular target for treating PEL and that CEP is quite useful as a unique therapeutic agent for PEL.


86. Dabaghmanesh N, Matsubara A, Miyake A, Nakano K, Ishida T, Katano H, Horie R, Umezawa K, Watanabe T: Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci; 2009 Apr;100(4):737-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a refractory malignancy caused by human herpes virus 8 (HHV-8) in immunocompromised individuals.
  • The tumor cells of PEL are characterized by constitutive NF-kappaB activation.
  • Thus, in search for a new therapeutic modality of PEL, we examined the effect of DHMEQ on PEL cells.
  • We confirmed constitutive activation of NF-kappaB with subcomponents of p50 and p65 in PEL cell lines.
  • Array analysis revealed that DHMEQ down-regulated expression levels of NF-kappaB target genes, such as interleukin-6 (IL6), Myc, chemokine (C-C motif) receptor 5 (CCR5) and NF-kappaB1, whereas it up-regulated expression levels of some genes involved in apoptosis, and cell cycle arrest.
  • DHMEQ did not reactivate HHV-8 lytic genes, indicating that NF-kappaB inhibition by DHMEQ did not induce virus replication.
  • DHEMQ rescued CB-17 SCID mice xenografted with PEL cells, reducing the gross appearance of effusion.
  • In addition, DHMEQ could rescue the PEL-xenograft mice.
  • Therefore, we suggest DHMEQ as a promising candidate for molecular target therapy of the PEL.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469019.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


87. Brimo F, Popradi G, Michel RP, Auger M: Primary effusion lymphoma involving three body cavities. Cytojournal; 2009;6:21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a human herpes virus-8 (HHV8)-associated large-cell non-Hodgkin lymphoma localized in body cavities and presenting as pleural, peritoneal, or pericardial lymphomatous effusions.
  • We describe herein a case of PEL affecting three body cavity sites in an immunocompetent patient.
  • An examination of the fluid by cytology showed large atypical lymphocytes with abundant basophilic cytoplasm, either central or eccentric nuclei having irregular outlines, and multiple prominent nucleoli.
  • A diagnosis of PEL was rendered.
  • Despite chemotherapy and valganciclovir, the disease progressed to involve the pleural and pericardial cavities and the patient died 5 months following the initial diagnosis.
  • Although PEL is a B-cell lymphoma, it is usually of null phenotype by immunohistochemistry, and can rarely aberrantly express T-cell markers, as seen in the current case.
  • The key to the diagnosis of PEL rests on identifying HHV8 in the neoplastic cells.
  • Therefore, restricting the term of PEL only to those cases that are HHV8 positive is important in order to differentiate PEL from other lymphomas that can present as serous effusions and that carry, in general, a more favorable prognosis than PEL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):62-7 [12801300.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):493-9 [9537479.001]
  • [Cites] Adv Cancer Res. 1999;76:121-60 [10218100.001]
  • [Cites] Eur Respir J. 1999 Nov;14(5):1231-4 [10596717.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] AIDS. 2001 Jan 26;15(2):280-2 [11216942.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):944-50 [12218212.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):456-60 [14990970.001]
  • [Cites] Acta Cytol. 2004 May-Jun;48(3):425-30 [15192964.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1567-9 [16847420.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] APMIS. 2009 Mar;117(3):222-9 [19245595.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Diagn Cytopathol. 1997 Aug;17(2):134-7 [9258621.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1528-37 [9850179.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):498-502 [10349390.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):753-5 [10782162.001]
  • [Cites] Am J Hematol. 2000 Dec;65(4):310-4 [11074561.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1112-5 [11167749.001]
  • [Cites] Arch Pathol Lab Med. 2001 Sep;125(9):1246-8 [11520284.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):330-4 [15023036.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Leukemia. 2005 Mar;19(3):473-6 [15674353.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):1022-7 [15824995.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Acta Haematol. 2007;117(3):132-44 [17135726.001]
  • [Cites] Cancer. 2008 Aug 25;114(4):225-7 [18473348.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1236-7 [18525275.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):101-4 [9013840.001]
  • (PMID = 19876384.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2762694
  • [Keywords] NOTNLM ; Effusion / Epstein–Barr virus / human herpes virus-8 / lymphoma
  •  go-up   go-down


88. Yiakoumis X, Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, Kontopidou FN, Kalpadakis C, Korkolopoulou P, Levidou G, Androulaki A, Siakantaris MP, Sachanas S, Andreopoulos A: Primary effusion lymphoma in two HIV-negative patients successfully treated with pleurodesis as first-line therapy. Anticancer Res; 2010 Jan;30(1):271-6
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) mostly occurring in HIV-positive patients.
  • We report two HIV-negative, HHV8-positive patients with PEL of the pleural cavity who achieved a durable remission after pleurodesis with bleomycin and no systemic therapy.
  • We also perform a review of the relevant literature regarding the clinical data, treatment, and survival of PEL in HIV-negative patients.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150647.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


89. Nemunaitis MC, Schussler JM, Shiller SM, Sloan LM, Mennel RG: Primary effusion lymphoma diagnosed by pericardiocentesis. Proc (Bayl Univ Med Cent); 2009 Jan;22(1):77-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL), formerly known as body cavity-based lymphoma, is a high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi's sarcoma and human herpesvirus 8 infection.
  • PEL is often diagnosed in patients with HIV infection and carries a poor prognosis, with median survival near 6 months.
  • We describe a patient who presented with symptomatic pericardial effusion, secondary to newly diagnosed PEL, and no prior history of HIV infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):447-55 [16093794.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):551-2 [15800785.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):77-82 [15662128.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3102-8 [15837766.001]
  • [Cites] Leukemia. 2005 Mar;19(3):473-6 [15674353.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Leukemia. 1999 May;13(5):664-70 [10374868.001]
  • [Cites] Am J Hematol. 1998 Mar;57(3):266 [9495391.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4894-900 [9389706.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] Clin Pharmacol Ther. 1978 Jan;23(1):68-72 [618710.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1699-704 [15343345.001]
  • [Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):439-43 [11378560.001]
  • [Cites] JAMA. 2001 Apr 11;285(14):1880-5 [11308402.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] AIDS. 2001 Jan 26;15(2):280-2 [11216942.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1792-801 [17568816.001]
  • [Cites] Oncologist. 2007 May;12(5):569-76 [17522245.001]
  • [Cites] J Cardiol. 2007 Apr;49(4):205-10 [17460882.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1849-50 [16766593.001]
  • [Cites] Int J Hematol. 2006 May;83(4):328-30 [16757433.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • (PMID = 19169406.001).
  • [ISSN] 0899-8280
  • [Journal-full-title] Proceedings (Baylor University. Medical Center)
  • [ISO-abbreviation] Proc (Bayl Univ Med Cent)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2626366
  •  go-up   go-down


90. Gasperini P, Sakakibara S, Tosato G: Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol; 2008 Oct;84(4):994-1000
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS)-associated herpesvirus is associated with the proliferative/malignant disorders KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD) in patients with AIDS.
  • In spite of recent advances in the treatment of KS, PEL and MCD represent therapeutic challenges.
  • Recent advances in dissecting the pathogenesis of these diseases have indicated that the viral cytokine IL-6 and the cellular cytokines/growth factors IL-10, IL-6, stromal cell-derived factor 1, and vascular endothelial growth factor are important contributors to the growth, survival, and spread of PEL and MCD and are therefore potential targets for drug development.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Animals. Antiretroviral Therapy, Highly Active. Cell Division. Cell Survival. Disease Models, Animal. Humans. Interleukin-10 / immunology. Interleukin-6 / immunology. Mice. Mice, Inbred NOD. Mice, SCID. Vascular Endothelial Growth Factor A / immunology

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 May 1;67(9):4042-51 [17483315.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Transplantation. 2007 Jul 15;84(1):40-5 [17627235.001]
  • [Cites] J Clin Invest. 1999 Nov;104(9):1199-211 [10545519.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1109-10 [10691336.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4672-7 [10779772.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33189-92 [10961983.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):495-506 [10952719.001]
  • [Cites] Eur J Immunol. 2001 Feb;31(2):350-9 [11180098.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2526-7 [11307774.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):965-9 [11581297.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3042-9 [11698289.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3473-5 [11719390.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2101-4 [12829785.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3900-5 [12907452.001]
  • [Cites] Science. 1988 Jan 29;239(4839):502-4 [2829354.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Physiol Rev. 1991 Jan;71(1):93-127 [1986393.001]
  • [Cites] J Exp Med. 1991 Nov 1;174(5):1275-8 [1940805.001]
  • [Cites] Semin Oncol. 1993 Dec;20(6):636-47 [8296200.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1243-54 [7632928.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Biol Chem. 1996 Jan 12;271(2):736-41 [8557680.001]
  • [Cites] AIDS. 1996 Jan;10(1):61-7 [8924253.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1198-201 [9129085.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4894-900 [9389706.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2475-81 [9516148.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Immunity. 1999 Jan;10(1):39-49 [10023769.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] Acta Oncol. 2004;43(8):698-704 [15764213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5 [15781862.001]
  • [Cites] J Med Chem. 2005 Oct 20;48(21):6661-70 [16220982.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):140-58 [16828973.001]
  • [Cites] J Virol. 2006 Oct;80(19):9811-21 [16973585.001]
  • [Cites] J Virol. 2006 Nov;80(21):10874-8 [16956953.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • (PMID = 18319288.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 130068-27-8 / Interleukin-10
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC2538598
  •  go-up   go-down


91. Sukhumsiirchart W, Kawanishi S, Deesukon W, Chansiri K, Kawasaki H, Sakamoto T: Purification, characterization, and overexpression of thermophilic pectate lyase of Bacillus sp. RN1 isolated from a hot spring in Thailand. Biosci Biotechnol Biochem; 2009 Feb;73(2):268-73
SILVA. SILVA SSU Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification, characterization, and overexpression of thermophilic pectate lyase of Bacillus sp. RN1 isolated from a hot spring in Thailand.
  • A thermophilic pectate lyase, Pel SWU, was isolated from a culture filtrate of Bacillus sp.
  • The molecular mass of Pel SWU was estimated to be 33 kDa.
  • The pel gene encoding Pel SWU was 1,023 bp, which corresponds to 341 amino acids.
  • The properties of the recombinant enzyme was similar to those of Bacillus Pel SWU.
  • Unsaturated di- and trigalacturonic acids were formed mainly as the final products of degradation by Pel SWU, as revealed by high-performance anion-exchange chromatography (HPAEC) and electrospray ionization mass spectrometry (ESI-MS) analyses.
  • This thermophilic pectate lyase should be useful in the degradation of pectin networks at high temperature.
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Gene Expression. Hydrogen-Ion Concentration. Molecular Sequence Data. Phylogeny. Recombinant Proteins / chemistry. Recombinant Proteins / genetics. Recombinant Proteins / isolation & purification. Recombinant Proteins / metabolism. Temperature. Thailand

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202269.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


92. Lietz A, Janz M, Sigvardsson M, Jundt F, Dörken B, Mathas S: Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis. Br J Haematol; 2007 May;137(4):342-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similar to classical Hodgkin lymphoma (HL) tumour cells, primary effusion lymphoma (PEL) originates from mature B cells but displays a non-B cell phenotype, the mechanisms and consequences of which are not yet understood.
  • This study showed that PEL lacked DNA binding activity of the B cell-determining transcription factors E2A, EBF and Pax5.
  • PEL overexpressed the E2A antagonists ABF-1 and Id2, which have been described to block the B-cell differentiation program in classical HL.
  • However, in contrast to HL cells, B lineage-inappropriate genes were not similarly upregulated in PEL, and reconstitution of B cell-specific E2A homodimer activity in PEL induced apoptosis.
  • These data demonstrate that lineage infidelity in PEL is not as pronounced as in HL, and that the loss of the B cell-specific transcription factor E2A in PEL is implicated in apoptosis protection.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Genes, Tumor Suppressor. Lymphoma / genetics
  • [MeSH-minor] Apoptosis. B-Cell-Specific Activator Protein / genetics. B-Cell-Specific Activator Protein / metabolism. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Blotting, Northern. Cell Differentiation. Cell Line. Cells, Cultured. DNA / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Electrophoretic Mobility Shift Assay. Gene Deletion. Humans. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. Trans-Activators / genetics. Trans-Activators / metabolism. Transfection

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456056.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / EBF1 protein, human; 0 / PAX5 protein, human; 0 / TCF3 protein, human; 0 / Trans-Activators; 9007-49-2 / DNA
  •  go-up   go-down


93. Stewart CJ, Brennan BA, Crook ML, Russell P: Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours. Histopathology; 2007 Sep;51(3):313-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.
  • AIMS: To determine whether elastin stains aid in classifying peritoneal implants associated with ovarian serous borderline tumours (SBT).
  • Elastin stains were performed using histochemical and immunohistochemical methods to demonstrate the peritoneal elastic lamina (PEL), and evaluated with regard to assessment of the subtype of implant.
  • The elastin stains demonstrated the PEL in most anatomical sites other than the omentum and the bladder and were considered helpful in 44/80 (55%) cases.
  • The staining was non-contributory in most of the remaining biopsies, because the PEL was not identified.
  • CONCLUSIONS: Demonstration of the PEL using elastin stains can be useful in the subclassification of implants associated with ovarian SBT and is of most value in confirming the superficial distribution of non-invasive lesions.
  • However, evaluation is limited by the absence of a defined elastic layer in a proportion of biopsy specimens, possibly reflecting their superficial location, as well as absence of a distinct PEL in sites such as the omentum.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727474.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-58-3 / Elastin
  •  go-up   go-down


94. Kobayashi Y, Kamitsuji Y, Kuroda J, Tsunoda S, Uoshima N, Kimura S, Wada K, Matsumoto Y, Nomura K, Horiike S, Shimazaki C, Yoshikawa T, Taniwaki M: Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature. Acta Haematol; 2007;117(3):132-44
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This primary lymphomatous effusion includes human herpes virus 8 (HHV8)-related primary effusion lymphoma (PEL) and HHV8-unrelated PEL-like lymphoma.
  • METHODS: Using 'PEL' and 'body cavity-based lymphoma' (BCBL) as key words, reports written in English were collected from PubMed.
  • Adding our 2 PEL-like lymphoma cases, each case was studied as to the patients' and lymphomas' characteristics, therapy and survival time.
  • CONCLUSIONS: Both PEL and PEL-like lymphoma are thought to be characterized by a peculiar proliferation, regardless of the presence of HHV8.
  • Dividing PEL or PEL-like lymphoma into two subgroups on the basis of HIV presentation might also be appropriate.


95. Wies E, Mori Y, Hahn A, Kremmer E, Stürzl M, Fleckenstein B, Neipel F: The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood; 2008 Jan 1;111(1):320-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human herpesvirus-8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus (KSHV), is etiologically linked to primary effusion lymphoma (PEL).
  • However, with few exceptions, these putative oncogenes were analyzed in heterologous systems only using overexpression of single genes.
  • We used RNA interference (RNAi) to knock down the expression of several KSHV genes in cultured PEL cells carrying the KSHV genome.
  • The viral interferon-regulatory factor-3 (vIRF-3) was found to be required for proliferation and survival of cultured PEL cells.
  • Surprisingly, although the related Epstein-Barr virus (EBV) is usually sufficient to immortalize human B lymphocytes, silencing of vIRF-3 reduced the viability of both EBV(-) and EBV(+) PEL cells.
  • This suggests that KSHV is the driving force in the pathogenesis of PEL.
  • [MeSH-minor] Apoptosis. Burkitt Lymphoma. Caspase 3 / metabolism. Caspase 7 / metabolism. Cell Division. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Humans. Multiple Myeloma. RNA, Small Interfering. Transfection

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890449.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / RNA, Small Interfering; 0 / Viral Proteins; 0 / viral interferon regulatory factors; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  •  go-up   go-down


96. Ahmad A, Groshong JS, Matta H, Schamus S, Punj V, Robinson LJ, Gill PS, Chaudhary PM: Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol Ther; 2010 Nov 15;10(10):1033-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an aggressive form of lymphoma that is associated with infection by Kaposi's sarcoma-associated herpesvirus (KSHV).
  • One of the KSHV genes expressed in PEL cells is K13, a potent activator of the NF-κB pathway.
  • A possible candidate that could cooperate with K13 in the development of PEL is c-Myc, whose expression is frequently dysregulated in PEL cells.
  • To study the cooperative interaction between K13 and c-Myc in the pathogenesis of PEL, we crossed the K13 transgenic mice to iMyc(Eμ) transgenic mice that overexpress Myc.
  • Lymphomas in the K13/iMyc(Eμ) mice also lacked the expression of B- and T-cell markers, thus resembling the immunophenotype of PEL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 May 4;25(19):2717-26 [16418726.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12885-90 [16120683.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Virol. 2006 Jul;80(14):7179-85 [16809323.001]
  • [Cites] J Gen Virol. 2007 Jan;88(Pt 1):46-50 [17170435.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Oncologist. 2007 May;12(5):569-76 [17522245.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]
  • [Cites] J Virol. 2007 Oct;81(19):10451-9 [17634226.001]
  • [Cites] PLoS One. 2007;2(10):e1067 [17957251.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31944-53 [17728244.001]
  • [Cites] Cancer Biol Ther. 2008 Apr;7(4):603-8 [18223318.001]
  • [Cites] Br J Haematol. 2008 Oct;143(1):3-15 [18573107.001]
  • [Cites] J Virol. 2009 Jan;83(2):598-611 [18987137.001]
  • [Cites] Nat Cell Biol. 2009 Nov;11(11):1355-62 [19838173.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Semin Immunol. 2000 Feb;12(1):85-98 [10723801.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1956-61 [12406869.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Leukemia. 2004 Jan;18(1):11-7 [14574329.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52437-45 [14563855.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] J Clin Invest. 2004 Jun;113(12):1763-73 [15199411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] Front Biosci. 1998 Feb 15;3:d250-68 [9468463.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] Oncogene. 1993 Oct;8(10):2741-8 [8397370.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):269-75 [7846125.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Behring Inst Mitt. 1996 Oct;(97):101-17 [8950469.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Blood. 1998 Jul 1;92(1):234-40 [9639522.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1317-22 [9721090.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2967-87 [10378693.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5738-46 [10523854.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1306-15 [15735016.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):469-73 [16093798.001]
  • [Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]
  • (PMID = 20818173.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085177; United States / NHLBI NIH HHS / HL / R21 HL085189; United States / NCI NIH HHS / CA / CA85177; United States / NHLBI NIH HHS / HL / HL085189
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Viral Proteins; 0 / viral FLIP protein, Human herpesvirus 8
  • [Other-IDs] NLM/ PMC3047095
  •  go-up   go-down


97. Boulanger E, Meignin V, Afonso PV, Duprez R, Oksenhendler E, Agbalika F, Gessain A: Extracavitary tumor after primary effusion lymphoma: relapse or second distinct lymphoma? Haematologica; 2007 Sep;92(9):1275-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HHV-8-associated solid lymphomas which develop in extracavitary sites during the course of primary effusion lymphoma (PEL) could represent the relapse of original PEL tumors in different anatomical sites, or newly occurring distinct HHV-8-associated lymphomas, such as multicentric Castleman disease-related microlymphomas.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma / complications. Lymphoma, AIDS-Related / complications. Neoplasm Recurrence, Local / complications. Pleural Effusion, Malignant / complications

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768127.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


98. Sarek G, Järviluoma A, Ojala PM: KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood; 2006 Jan 15;107(2):725-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All PEL cells are latently infected with KSHV and express latent viral proteins such as the viral cyclin (v-cyclin), which has previously been implicated in down-regulation of cell-cycle inhibitor p27(KIP1) levels via phosphorylation on Thr187.
  • PEL cells retain high levels of p27(KIP1) but yet proliferate actively, which has left the biologic significance of this p27(KIP1) destabilization somewhat elusive.
  • We have recently demonstrated that v-cyclin and p27(KIP1) stably associate in PEL cells.
  • Here we demonstrate that v-cyclin together with its kinase partner CDK6 phosphorylates the associated p27(KIP1) in PEL cells, which represent a biologically relevant model system for KSHV pathobiology.
  • Interestingly, upon reactivation of KSHV lytic cycle, v-cyclin-CDK6 phosphorylated p27(KIP1) on Thr187, which resulted in down-regulation of p27(KIP1) protein levels.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160006.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclins; 0 / HHV8-Vcyc protein, Human herpesvirus 8; 0 / Viral Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


99. O'Hara AJ, Wang L, Dezube BJ, Harrington WJ Jr, Damania B, Dittmer DP: Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood; 2009 Jun 4;113(23):5938-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that the absence of miRNAs likewise can be used to determine tumor origin (miR-155) and proliferation state because tumor suppressor miRNAs (miR-222/221, let-7 family) were significantly down-regulated in primary effusion lymphoma (PEL) and in Kaposi sarcoma (KS), an endothelial cell tumor.
  • PEL and KS are associated with KS-associated herpesvirus infection.
  • Because many tumor suppressor proteins are wild-type in KS and PEL, down-regulation of multiple tumor suppressor miRNAs provides a novel, alternative mechanism of transformation.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] J Virol. 2007 Feb;81(4):1912-22 [17121789.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]
  • [Cites] EMBO J. 2007 Aug 8;26(15):3699-708 [17627278.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9762-70 [17942906.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2347-53 [18079361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 [18308936.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2773-80 [18413744.001]
  • [Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4640-8 [18559509.001]
  • [Cites] J Virol. 2002 Aug;76(16):8383-99 [12134042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):982-9 [15572730.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3068-71 [16849646.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • (PMID = 19252139.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL083469; United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA096500; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121935; United States / NCI NIH HHS / CA / CA121947; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NIAID NIH HHS / AI / T32 AI00741; United States / NHLBI NIH HHS / HL / R01 HL083469; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / R01 CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2700328
  •  go-up   go-down


100. Glaister BC, Orendurff MS, Schoen JA, Klute GK: Rotating horizontal ground reaction forces to the body path of progression. J Biomech; 2007;40(15):3527-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When studying the biomechanics of a transient turn, the orientation of the body will change relative to the orientation of the force plates over the progression of the turn.
  • Body reference frames were chosen whose origins were the center of mass (COM) and the pelvis origin (PEL).
  • A finite-difference method was used to align the axes of the reference frames according to the horizontal paths of the COM and PEL.
  • The ground reaction impulses (GRIs) were calculated relative to the COM and PEL reference frames.
  • GRI differences were small between the PEL and COM frames, suggesting that either is acceptable for turning studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597134.001).
  • [ISSN] 0021-9290
  • [Journal-full-title] Journal of biomechanics
  • [ISO-abbreviation] J Biomech
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement